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Background: Musculoskeletal disorders (MSDs) appear relatively frequent and are costly for 
society each year, yet they are poorly understood. Four commonly occurring MSDs are Chronic 
Fatigue Syndrome (CFS), Back Pain (BP) of unknown origin, Fibromyalgia (FM), and muscle 
pain/Myalgia. There are few Norwegian epidemiologic data on these four outcomes. Physical 
activity (PA) has been internationally recognized as having a protective effect against chronic 
disease. The association between PA and these four outcomes is not well understood and the 
main aim of this study was to investigate this relationship in a large prospective cohort of 
Norwegian women. 
Methods: Self-reported data were gathered from 76 367 women in the nationally representative 
cohort study the Norwegian Women and Cancer study. Data were gathered on total amount of PA 
at enrolment and of the four outcome conditions during follow-up, in addition to covariate 
information. We calculated incidence rate and total prevalence. The association between PA and 
the four outcomes was assessed using multivariate logistic regression analysis. Prevalent cases 
were excluded from logistic regression analysis. PA was assessed for trend and as a categorical 
variable. 
Results: Incidence densities per 100 000 person years were calculated to be as follows: CFS 411, 
BP 1268, FM 287, and myalgia 1509. Total prevalence was found to be 2.58% for CFS, 13.65% 
for BP, 5.02% for FM, and 17.87% for myalgia. These were comparable to age-standardized rates 
for the corresponding Norwegian female population. There was a significant trend (p < 0.001) 
that increasing levels of PA were associated with a reduced risk CFS, BP and FM. Compared to 
moderate PA level, very low levels of PA was significantly associated with increased risk of CFS 
(OR 1.61 (CI 1.38-1.88)), BP (OR 1.17(CI 1.04-1.31)), and FM (OR 1.30(CI 1.07-1.58)). For 
CFS, PA levels low (OR 1.31 (CI 1.19-1.44)) and very high (OR 1.18 (CI 1.01-1.38)) were also 
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associated with an increased risk of PA. The results showed no significant associations between 
PA and mylagia.  
Conclusion: Our study found nationally representative data for incidence and prevalence of CFS, 
BP, FM, and myalgia in Norwegian women. When compared to moderate levels of total PA, very 
low PA was associated with an increased risk of CFS, BP, and FM. Low and very high levels of 
PA were associated with an increased risk of CFS. More studies are needed to confirm the 
incidence for these outcomes in the Norwegian population, and to investigate the association 
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1. Purpose of the thesis 
The Norwegian Women and Cancer (NOWAC) study is a longitudinal study originally developed 
to study the relationship between female cancer and internal and external hormones. The study 
has self-reported information on women’s level of physical activity (PA), as well as prevalence 
and incidence of some musculoskeletal disorders (MSDs), four of which were of particular 
interest: chronic fatigue syndrome (CFS), back pain (BP) of unknown origin, fibromyalgia (FM), 
and myalgia. These conditions are part of the category of disorders which contributes to a large 
proportion of health care expenses, disability and morbidity in the population (1-4), and yet there 
is a lack of national epidemiologic data and international understanding as to what might be their 
cause. At the same time, there is a substantial amount of evidence indicating that PA is a 
protective factor against many conditions causing morbidity and mortality (5-7). This led us to 
ask the research questions: What is the incidence/prevalence of these conditions among 
Norwegian women? What is the association between levels of physical activity, and chronic 














There exists a broad variety of different definitions and groupings when it comes to MSDs today. 
Commonly included are rheumatic and degenerative conditions such as rheumatoid arthritis 
(RA), Bechterew, osteoarthritis and osteoporosis. A third and less rigidly defined group, which is 
often partially or fully included when discussing MSDs, contains the conditions CFS, back pain 
of unknown origin, FM, and myalgia. These conditions might not seem intuitively connected to 
each other, but the World Health Organization (WHO) has given some general descriptions on 
the central characteristics of such ailments, calling them a diverse pathophysiological group 
linked by anatomy and associations to physical impairments and pain (8). Although MSDs rarely 
cause mortality in the ill individual compared to many other conditions, they are nevertheless 
“more prevalent. They are a major cause of pain and reduced quality of life” (9). In Europe, 
reports have stated 60% of work disability to be caused by MSDs (10), and 2005 numbers from 
the USA indicated that 50% of above-18 year olds experienced an MSD lasting more than 3 
months during the previous year (9). These numbers are more than mirrored in the Norwegian 
population (2). Norway has a higher prevalence of moderate or strong, chronic pain conditions 
than most other European countries (2). This group of conditions accounts for 46% of all sick 
leave and 33% of disability pensions in Norway (11).The Norwegian prevalence for this group of 
conditions increased by 21% from 1995 to 2000, and were responsible for 49% of the 1-year sick 
leaves in Norway in 2000 (12). The annual costs of health care for treating MSDs in Norway, 
including medication, general practitioner visits, examinations and manual treatments, totaled 
14.3 billion NOK in 2009 (2). When including all other societal costs – social security benefits, 
disability pensions, production losses etc. – this sum approached 73 billion NOK, annually. It is 
apparent that these relatively common ailments, despite being poorly understood, constitute 
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extensive costs for the society each year, both in form of great amounts of suffering and disability 
for the affected individuals, as well as vast economic costs for patients, employers and 
governments.  
 
The one group of MSDs that has remained perhaps the least understood one is that of the 
‘diffuse’ character – the large variety of treatment modalities that exist for chronic pain 
conditions highlight the present difficulties of treating such conditions effectively (13). For such 
conditions as the four selected from the questionnaires of the NOWAC study, it is often not 
possible to set a specific diagnosis, and many patients have ended up being diagnosed according 
to symptoms (2). CFS, back pain of unknown origin, FM, and myalgia are all extensive problems 
causing large amounts of suffering and costs while remaining relatively difficult to treat due to 
the obscure nature of the conditions. Understanding of the epidemiology of chronic pain 
conditions remains poor despite this being one of the most common causes of contact with the 
health care services (14). In Norway in 2006, 5% of the new permanent disabilities reported FM 
as the primary diagnosis (2). The prevalence of chronic widespread pain has been reported to 1% 
- 15% (15). Devanur and Kerr suggested a world-wide prevalence of CFS between 0.4% - 1.0% 
(16). The annual prevalence of low back pain (LBP) – typically of unknown origin – is reported 
as 25% - 60% (10), with a total lifetime prevalence from 11% - 84% (1).  
 
Women have been reported to experience pain-related musculoskeletal conditions more 
frequently than men (13). Furthermore, MSDs have been reported to be the foremost reason why 
Norwegian women seek polyclinic care (11). The nature of this difference between the genders 




Woolf and Pfleger reported that higher age causes an increase in the prevalence of many different 
MSDs, and that they can be affected by lifestyle habits, PA and body tissue composition (8). 
Mielenz and Alvarez reported that both pain and risk of mortality from certain MSDs could be 
prevented with regular exercise (13). As the four outcome conditions of our study belong to the 
same general musculoskeletal category as rheumatic and degenerative conditions, it could be 











3. Background and theory 
In order to adequately explore the research question, background knowledge was needed 
regarding the incidence and prevalence of our outcomes, as well as the association of PA to the 
four different outcomes in our study. We explored what was known about this relationship, and 
what results were to be expected, as well as where theory might be lacking. Furthermore, we 
needed explore the relationship between women and the exposure and outcomes used in our 
study. Finally, we examined whether any of the reported covariates have a potentially 
confounding effect on the relationship between PA and outcomes. 
3.1 Women’s health 
Health as a worldwide phenomenon displays some differing distribution when separating the 
genders. Women’s health is affected to a different degree by cultural, societal, economic and 
genetic factors than that of men, causing women to face higher health costs than men due to using 
more health care (17). Several gender disparities in health are not confined to the developing 
world but are found consistently in all regions of the globe (17). One such disparity relates to the 
‘modern epidemic’ of MSDs. Women generally have more sickness absence and long-term 
disability caused by MSDs, and have a suggested increased risk of obtaining chronic MSDs (18).  
 
The cause of the great disparities in MSDs between genders remains unknown, but Meeus et al. 
pointed out that gender was a potential confounder when studying pain phenomena: this includes 
women often having lower thresholds, greater ability to discriminate higher pain ratings, and less 
tolerance of noxious stimuli than males. Furthermore, women report greater levels of pain 
catastrophizing (19). This does not necessarily mean that women are over-reporting ‘normal’ 
experiences as sickness, but could just as easily imply that men are more insensitive and prone to 
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suppress or be unaware of much of their own bodily experience (20). Furthermore, some authors 
have suggested the “double-burden” theory as a possible explanation why women experience 
disabling MSDs more frequently, pointing out that facing stressors both in the occupational and 
the domestic arena might lead to the development of such conditions (18). Whichever theory one 
chooses, a potential explanation lies with the fact that women have a lower threshold for seeking 
out medical attention compared to men (20, 21). Conditions such as CFS and FM have long been 
recognized to primarily affect women, although there have been suggestions that the number of 
unreported cases among men are extensive. This could potentially imply a bias towards the null 
in male prevalence of CFS and MSDs, with unknown numbers of undiagnosed cases.  
3.2 Physical activity 
PA is internationally recognized as having a protective effect against a broad variety of 
communicable and non-communicable diseases. According to the WHO;  
Insufficient physical activity is the fourth leading risk factor for mortality. Approximately 
3.2 million deaths and 32.1 million DALYs (representing about 2.1% of global DALYs) 
each year are attributable to insufficient physical activity. People who are insufficiently 
physically active have a 20–30% increased risk of all-cause mortality compared to those 
who engage in at least 30 minutes of moderate intensity physical activity on most days of 
the week (5, p18) 
PA has many positive effects on both physiological and psychological processes. Lee et al. 
reported, among others, cardiorespiratory and muscular fitness, increased functional health and 
improved cognitive function all to derive from healthy PA (7). Adversely, too little PA leading to 
a sedentary lifestyle is a risk factor for depression, metabolic syndrome, and all-cause mortality, 
among others (7).  
 
Increasing PA appears to be protective against morbidity and mortality. The WHO maintains that 
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there is a dose-response relationship between higher volumes of PA and risk of cardiovascular 
disease and diabetes (22). However, they also stated that there was a lack of evidence 
demonstrating an additional preventive effect against non-communicable diseases when 
exceeding 300 minutes per week of PA (22). The present general consensus of recommendations 
on daily levels of PA is that people of all ages should participate in 30 minutes of at least 
moderately strenuous PA, preferably all days of the week (23). Adding more moderate-intensity 
activity can add to the health benefits gained (24). Of the 31% of adults who are insufficiently 
active across the globe, there are 6% more women than men (28% and 34%, respectively) (5). 
These numbers are increased when looking at high-income countries, where a total of 48% of 
women are insufficiently physically active, and this inactivity increases with age (5, 25). In 
Norway, approximately 1/3
rd
 of the population was reported to be physically inactive in the 
decade leading up to the year 2000. This included one in every five women. The number of 
physically inactive persons has since been declining; as of 2012, 6% of women aged 45-66 years 
were inactive, compared to 14% of the corresponding men (26). These numbers were slightly 
higher for younger women, and slightly lower for younger men.  
 
One probable determinant of decreased PA in high-income countries is an increasingly 
automatized daily life (5). However, Bauman reported that high-income countries, whilst having 
a lower degree of PA as manual labor, had a higher degree of total leisure time PA (27). This 
visualizes the fact that PA consists of several subsets of activities. PA as a term is quite general 
and describes all such “bodily movement that is produced by the contraction of skeletal muscles 
that increases energy above the basal level” and that significantly increases the amount of energy 
used (24). Gabriel et al. stated PA to be such activity that “involves human movement, resulting 
in … increased energy expenditure and improved physical fitness” (28). The same authors sorted 
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all such movements that are carried out through the day into four sub-categories, depending on 
the context in which they took place. The suggested categories PA is performed in are 
exercise/leisure, occupational/educational setting, household/caretaking/domestic, and 
transportation (24, 28). The U.S Department of Health and Human Services defined exercise as 
“planned, structured, repetitive and purposive in the sense that improvement or maintenance of 
one or more components of physical fitness is the objective” (24), with the following aspects of 
physical fitness having been shown to be health related: “cardiorespiratory fitness”, skeletal 
muscular strength and endurance, as well as body composition and flexibility (24). This describes 
a link between PA in the form of exercise, and increased health benefits and protective effects. 
Hallal et al. reported that activity in form of transportation had a protective effect against all-
cause mortality and several kinds of morbidity (29). In this respect, PA in commuting could be 
similar to PA in the form of exercise. Physically intensive work in the occupational setting 
however, has been shown to be a risk factor for MSDs, and was cautioned against in a report by 
the Norwegian National Institute for Occupational Health (30). Aas et al. reported that repetitive 
work and working in awkward positions as well as occupational exposures that induce 
psychosocial work strain and stress were risk factors for deteriorating health. This problem would 
be exacerbated in populations that were both inactive and physically unfit (30). PA in the 
occupational/educational setting thus needs not incur the protective effect of exercise, but might 
instead have an inverse effect on health. This means that PA consists of different kinds of activity 
domains that can either promote or possibly deteriorate health. 
 
It has been suggested that level of PA can be a measure to distinguish people’s individual health 
behavior profiles (31). A proposed reason for this is that one can frequently observe a clustering 
together of positive and negative health behaviors, so that population groups with high levels of 
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inactivity would also display other hazardous lifestyle characteristics (31). Furthermore, like 
many other lifestyle variables in society, type of PA is also seen to follow the socioeconomic 
strata, relating to what amount of time is spent performing the different types of activities 
included in the general term PA: leisure time PA has been demonstrated to be highest in higher 
levels of socioeconomic strata, while occupational PA is highest among the lowest 
socioeconomic strata (32). Since these two have been suggested to have contradictory effects on 
health, the health effects of PA could be hypothesized to follow socioeconomic stratification.  
3.3 Outcomes 
The reported outcomes of our study were CFS, BP, FM and myalgia. When looking at the 
background of these outcomes, we examined the main understanding of these conditions in 
literature today, as well as epidemiologic data, and their gender distributions. Finally, we 
investigated how theory links the outcomes to PA.  
 
3.3.1 Chronic fatigue syndrome  
CFS is a condition that is marked by persistent and recurring fatigue for more than six months. 
This is accompanied by secondary symptoms which include impaired memory and concentration, 
soreness of the throat, sleep-disturbances and headache, as well as chronic, persistent and 
widespread musculoskeletal pain (19). Modern criteria for diagnosing CFS were suggested by the 
American Centers for Disease Control and Prevention (CDC) in 1994 (19). A 2006 review of 
CFS suggested the world-wide prevalence rate to be approximately 0.4-1% (16). Based on the 
case definition suggested by the CDC in 1994, one community-based study from 1999 in the US 
by Jason et al. suggested a prevalence rate of 0.522% (33). Another community-based study by 
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Reyes et al. from 2003 suggested a point prevalence for women of 373 per 100 000 persons (34). 
They also reported an incidence of 180 per 100 000 persons. Prins et al. reported one incidence 
rate from 1997 in a US setting to be 0.37% (35). Current epidemiologic data for the Norwegian 
setting seem to be lacking. As of 2013, the Norwegian prevalence rate of CFS was unknown. 
Point prevalence, given a similarity to international levels, was estimated at around 10 000 – 
20 000 cases by the Norwegian Directorate of Health (36).  
 
Today, the 1994 definition from the CDC is the most widely supported scientific case definition 
(16, 35). Fatigue is an often emphasized symptom in CFS, but myalgia has been shown to be a 
just as important and prevalent one as 94% of CFS patients experience muscle aches and pain 
(19). Such patients’ symptoms are typically exacerbated after levels of exercise that had 
previously been well-tolerated (19). Musculoskeletal pain appeared to be the most disabling 
aspect of CFS, as this accounted for up to 33% of limitations in activity level (19). Some 35-70% 
of CFS patients have also been suggested to meet criteria for FM (19). 
 
3.3.1.1 The development and theory of chronic fatigue syndrome  
Guidelines for research and clinical evaluation of CFS were revised in 1994 by the CDC, USA, 
and the International Chronic Fatigue Study Group (37). This was an update of the more 
restrictive approach employed by the 1988 CFS working case definition suggested by Holmes et 
al. (38). In the new guidelines, the CDC characterized CFS as consisting of severe and disabling 
fatigue, and a combination of other symptoms including cognitive impairment, sleep disturbance 
and musculoskeletal pain (37). There were and are no laboratory tests available to confirm this 
condition, causing clinicians to have to rely on clinical presentation of symptoms for diagnosis. 
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In 1994, 14-15.3% of the adult population in the US reported chronic fatigue lasting 2 weeks or 
longer with no medical cause (37). The CDC at this time suggested defining chronic fatigue as 
fatigue lasting > 6 months. Persistent or relapsing chronic fatigue had to be of such a nature that 
it was not alleviated by rest, and resulted in reduction of previous social, occupational, 
educational and personal activities of a substantial magnitude (35). This chronic fatigue, 
combined with four or more of the following symptoms; “cognitive impairment, sore throat, 
tender cervical or axillary lymph nodes, muscle pain, pain in several joints, new headaches, 
unrefreshing sleep, malaise after exertion”, was sufficient cause to assert a case of CFS. This 
given that the additional symptoms lasted six months or longer. Where the 1988 working case 
definition had required 8 out of a list of 11 symptoms to be present, the CDC now proposed 4 out 
of 8 to be sufficient. The CDC group also pointed out the existence of overlapping disorders, 
amongst others FM, but maintained that such disorders were not sufficient cause to explain 
chronic fatigue (37). During the early years of the disorder, there has been some controversy 
surrounding the naming of the illness. Scientists have preferred using CFS, since patients are 
identified by their symptoms and disabilities, as well as exclusion of other explanatory causes, 
instead of by objective physical findings or laboratory test results (35). Patients and clinicians, on 
the other hand, preferred using the term Myalgic Encephalomyelitis (ME). Patients were 
historically reluctant to the term CFS due to the linkage of this by the WHO to psychiatry in the 
name Neurasthenia in the ICD system. Due to this, they kept ME classified as a neurological 
conditions, while patients’ organizations began using the name CFS/ME (35). The 1994 report by 
the CDC was opposed to such a mixing of terms, fearing confusion and undermining of public 
attention to the disorder. They maintained that more information on pathophysiological processes 
was needed before changing the name. As of today, the term CFS/ME is commonly used in 
clinical practice and literature, while ICD-10 codes for two different variants: G93.3 Benign 
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Myalgic Encephalomyelitis, which is termed as a “postviral fatigue syndrome”; and F48.0 
Neurasthenia, which is termed as a neurotic disorder and fatigue syndrome, and is the one 
specified by the WHO. The diagnostic criteria appear to be similar, but G93.3 must be preceded 
by an infectious event and is a differential diagnosis to neurasthenia (39).  
 
Several explanatory mechanisms behind CFS have been suggested, such as endocrine disruptions, 
brain abnormalities, psychiatric comorbidities (depression and anxiety in particular), infectious 
origins, and that of central pain processing pathways being sensitized (1). It has also been pointed 
out that serious and stressful life-situations, like losing a job or loved one, often lead up to the 
disorder (35). Due to both CFS and FM being marked by inter-relation of pain-processing 
mechanisms, stress regulation and adverse life experiences, they have been suggested for the term 
“stress disorders” (35). However, the search continues for biological markers and causation (16).  
 
3.3.1.2 Chronic fatigue syndrome and women 
CFS has been reported to be a condition primarily affecting women, with a female-male ratio of 
6:1 (16). One community based study from Kansas reported point prevalence among US women 
to be between 0.21-0.54% (34). Bradley et al. reported that women comprised about 70% of the 
total amount of CFS prevalence (40). Jason et al. reported a female point prevalence of 0.32-
0.72% (33). In Norway, health authorities expect women to follow this pattern of higher 




3.3.1.3 Chronic fatigue syndrome and physical activity 
The link between pre-diagnosis habitual levels of PA and probability of contracting the disease is 
not well understood or explored in the literature. One low-powered case-control study by Smith 
et al. found that individuals who had developed CFS reported higher premorbid levels of PA 
compared to after having developed the condition (41). In addition, their premorbid levels of PA 
were rated as high. Premorbid PA levels were reported to be higher than for healthy controls. 
However, it should be noted that Nijs et al. reported that “continuing to be active despite 
increasing fatigue is likely to be a crucial step in the development of CFS” (42), implying that PA 
regardless of adverse warnings given by the body might have a reversed effect. It could be that 
the patients in the study by Smith et al. continued with high levels of PA despite feeling 
increasingly fatigued. Furthermore, based on what theory states about PA and its protective effect 
for so many other conditions, the expected hypothesis would be that higher levels of PA should 
be protective also for CFS.  
 
Many patients with CFS perceive PA as more exerting than healthy individuals (41). All included 
articles in a review by Nijs et al. reported reduced habitual PA among patients with CFS 
compared to healthy controls (42). They also found evidence of reduced peak isometric muscle 
strength in patients with CFS. They concluded that CFS patients did less amounts of PA during 
daily life and had less muscle strength. This may not be a surprise, given that too vigorous 
exercise – as little as a 30% increase - has been demonstrated to trigger relapses, possibly 
explaining some of the inactivity seen in CFS patients (42). Inactivity and exacerbation seem not 
to be linked to physiological capacity - Prins et al. suggested that patient inactivity, rather than 
being caused by physical fitness, actually was caused by perceptions and expectations (35) – that 
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fearing a relapse of symptoms leads to fear-avoidance behavior towards PA. The level of this 
kind of behavior was an important determinant of disability (42). Because musculoskeletal pain 
appears to be the most debilitating factor in CFS, it is intuitive to believe that having CFS would 
affect the level of PA.  
 
3.3.1.4 Implications of change in diagnostics for the present study 
The relatively limited interchangeable use of the terms CFS and ME might have caused some 
confusion to patients that had received the name of one during diagnosis from a physician, but 
not the other. We believed this problem to be of limited extent in relation to our study, as the term 
CFS which was used in the questionnaire was also the one which had been most consistently used 
throughout the history of the diagnosis, and which remains linked to ME and the ICD-10 today. 
Any patient diagnosed with ME is likely to be aware of the alternative name. Of possible greater 
importance is the change in diagnostic criteria in -94, which occurred during the follow-up time 
for our study. This might have caused some patients to migrate into or out of the diagnostic group 
at a greater number than usual, due to previous misdiagnosis of a similar condition. 
 
3.3.2 Back pain of unknown origin 
Lifetime prevalence of any type of BP has been reported from 11% and up to as high as 84%, and 
adult yearly incidence in industrialized countries at 5% (1, 3). It is the greatest sub-group within 
MSDs in Norway, and the one that causes the most sick leave and disability payments (11), with 
costs at 13-15 billion NOK per year (43). Today there exists international consensus on dividing 
BP into three categories: 1) specific back pain, 2) back pain of neurologic causes, and 3) non-
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specific back pain (back pain of unknown origin) (1, 3, 44). This “diagnostic triage” was 
suggested by Waddell in 1987 and has been in use since then (45). Specific back pain comprises 
all BP conditions of known pathologic origins, such as fractures of the back, infections, cancer, 
and rheumatic/inflammatory conditions (46). Back pains of neurologic causes encompass 
radiculopathies, spinal stenosis or pain caused by hernia of the intervertebral disc (3, 44). The 
non-specific group totals 80-90% of all BP cases, and is usually located to the lower back (1, 3, 
44). Duration of LBP is divided into acute (< 6 weeks), and chronic (> 12 weeks) (3, 46). These 
can be both radiating and non-radiating of nature (3, 44). Up to 80% of the population is 
estimated to experience LBP at some point during life, the lifetime prevalence rate (47), of which 
85-90% of LBP cases are of unknown origin (3, 48). In the perused literature, the expressions 
“back pain” and “low back pain” were used interchangeably, and no great effort was made to 
separate them when referring to the three categories in the diagnostic triage. Especially the group 
of non-specific BP was frequently assumed to occur in the lower back (3, 43). With most cases of 
BP being of unknown origin, and with most cases of BP of unknown origin being located at the 
lower back, and with most of LBP cases being of unknown origin, it seemed reasonable to 
assume that most reporting on “back pain of unknown origin” referred to non-specific LBP. 
Therefore, in our study, the term “back pain” was used as synonymous to this group.  
 
3.3.2.1 The theory of back pain 
The theoretical understanding of BP has a long history of difficulties. Waddell mentioned as early 
as 1987 that there was a lack of the biomechanical and pathologic understanding necessary to 
identify pathologic or even anatomic sources of pain (49). He suggested distress and illness 
behavior to be an important part of the condition, improving or deteriorating depending on the 
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success of the treatment, and stated that BP patients must be seen in light of a biopsychosocial 
model for illness and disability. Another suggestion was to separate those few with clear 
pathology from the vast amount of cases that lacked any clear cause. Thiese et al. reported that 
there is still a lack of consensus on the causes of most cases of LBP (50). Explicit descriptions of 
classic BP cases are hard to come by in the literature. Epidemiologic studies of BP have 
difficulties with heterogeneity with their selections, making the phenomenon hard to measure 
(51). Dionne et al. suggested a two-way definition for prevalence studies on BP: the first, a 
minimal definition with one “question covering site of low back pain, symptoms observed, and 
time frame of the measure, and a second question on severity of low back pain” and a more 
optimal definition “that is made from the minimal definition and add-ons” (51). The NOWAC 
study does not contain any such measurement instrument for BP, and so prevalence and incidence 
could not be ascertained in this optimal manner. Nevertheless, the theory from above on what 
“back pain of unknown origin” probably describes, might justify using this manner of self-
reporting as a measure of an approximate incidence and prevalence. 
 
3.3.2.2 Back pain and women 
Senie found that women reported higher percentages of BP across all age groups, and that the 
consequences of BP were higher across all age groups as well. The same was true for women 
across all levels of socioeconomic status, and that women of low socioeconomic status reported 
BP even more frequently (52, 53). These gender differences persisted across age, race and 
ethnicity groups. In Norway, painful conditions of the back were reported as one of the 
dominating groups of MSDs causing disability in women (54). Shiri et al. reported that obesity in 
women was a risk factor for BP (10).  
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3.3.2.3 Back pain and physical activity 
It has been reported that subjective measures of PA displayed a protective effect against BP, but 
primarily when PA was performed as leisure activity (50). The European Guidelines for 
Prevention in Low Back Pain state that there is a protective effect in leisure PA against BP (55). 
Thiese et al. found that PA was protective for developing LBP at moderate levels of PA (50). 
They suggested that there was a ceiling effect for PA, with higher levels not contributing any 
additional protective effect. Linton et al. also reported consistent evidence for the preventive 
effect of exercise on neck and back pain (56). Take note that they were talking about exercise in 
specific. There might be a divide between PA in general, and exercise in particular, when talking 
about preventive effect. This would be in concordance with the theory of PA, and the reported 
possible harmful effect of PA in the occupational setting (30). A recommended preventive 
lifestyle intervention for BP is to undertake moderate exercises multiple times every week and to 
maintain a physically active lifestyle (48).  
 
3.3.3 Fibromyalgia 
The epidemiology of FM has been reported to not be adequately investigated (57). Weir et al. 
reported to have calculated the first incidence rate (per 1000 years) for a large population. Age 
adjusted incidence for men was 6.88:1000, and 11.28:1000 for women (57). The diagnostic 
criteria for FM which are primarily used today are based on revised criteria for FM developed in 
1990. These state the following symptoms to be met: “History of widespread pain >3 months”, 
“Pain in 11 of 18 tender point sites”, and a list of clinical symptoms including fatigue, tenderness, 
sleep, stiffness, depression, dyscognition, and a reduced quality of life (58). The condition was 
summed up in a review by Mease from 2005 to be a marked primarily by chronic, widespread 
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pain, and multiple tender points throughout the body. Together with Ablin et al. he also described 
a range of other symptoms, including sleep disturbance, fatigue, irritable bowel syndrome, 
headaches, and mood disorders (59, 60). The most recurring symptoms were pain, fatigue and 
sleep disturbances. Virtually all patients described severe fatigue despite adequate sleep, which 
normally worsened by mid-afternoon. Mease also reported poor sleep patterns (59). Recurring 
descriptions of the condition by patients are typically likened to having the flu, together with a 
generalized pain sensation (58). The level of disability and impairment attained from the disease 
is high; Mease reported that FM patients scored lower than all others when compared to patients 
with RA, osteoarthritis, permanent ostomies, chronic obstructive pulmonary disease, and type 1 
diabetes (59). Furthermore, the disability one gets from FM does not seem to change over time 
(59).  
 
FM is often reported to coexist with other similar pain syndromes, such as headache and irritable 
bowel syndromes, depression, and CFS (61). 22% of FM patients have been reported to have 
depressions also (58). Especially CFS and FM appear to have substantial overlap of symptoms, 
and 50-70% of FM patients were reported to have a current or past diagnosis of CFS (61). 80% of 
FM patients will fulfill the criteria for CFS also (58). Thus, epidemiologic assessments of FM 
prevalence and incidence suffer from some uncertainty due to the extensive overlap of symptoms 
with CFS (13). Mielenz and Alvarez suggested this measurement bias to be one of underreported 
FM, but this could possibly go both ways. 
 
3.3.3.1 History and theory of fibromyalgia 
The first differentiation from the general ‘muscular rheumatisms’ commonly referred to in the 
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1800s, to the term “fibrositis”, occurred in 1904 (62). It was then suggested that the condition 
was one of fibrous muscle tissue inflammation (62). The first modern description of the 
“fibromyalgia syndrome” was presented in 1972, when Smythe described fibrositis symptoms as 
including tender points and widespread pain, along with certain clinical information, and 
specifying sites of tender points (62). This led to an increased interest surrounding the condition, 
with the term “fibromyalgia” appearing in 1976. Research continued until 1990, when the 
Multicenter Criteria Committee, headed by the American College of Rheumatology (ACR), 
developed the consensus definition of the condition FM as seen previously (63). Although 
theories of causation remained diverse, these criteria and definitions of the FM syndrome have 
remained relatively unchanged since the ACR report. By 1999, there had been no 
pathophysiological findings in muscle- or soft tissue to indicate localized pathology. Thus it was 
reported in 1999 that the search for causation was shifting towards neuroscience (61). By 2004, 
authors stated that “the pathogenesis of this disorder now is accepted to be an aberration of 
central neurohormonal functions, particularly central sensitization” (62). A 2005 review stated 
possible precipitating causes to be stress, medical illness, pain conditions, neurotransmitter and 
neuroendocrine disturbances (59). They too pointed towards a sensitization of the central nervous 
system (CNS), as well as the periphery, as the main disturbance. Genetic factors have also been 
suggested as an underlying cause (13).  
 
3.3.3.2 Fibromyalgia and women 
As in many other chronic widespread pain conditions, women are also overrepresented in FM, 
with a suggested rate of 7:1 for women compared to men (57). This ratio was based on the 1995 
prevalence of Wolfe et al., who reported a total point prevalence of 2% for both sexes, but 3.4% 
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for women and 0.5% for men (64). In Norway, prevalence from one epidemiologic study was 
reported at 3.2%, with the prevalence of women being 5%, and with women making up 90% of 
adult FM patients (2). The form of prevalence rate was not clear but appeared to be total 
prevalence within selection. Women with FM also comprise the largest national group of new 
disability pensions (4, 54). In total, around 1750 new disability pensions are due to FM each year 
in Norway (2). Particular risk factors for women have been suggested to include autoimmune 
disorders, systemic inflammatory conditions, as well as endometriosis (13). The exact reason why 
women seem to be affected more often than men - or become more disabled by the condition than 
men - is unknown. As previously discussed, underreporting among men could inflate the women-
men ratio and make it appear as if women were overrepresented in FM.  
 
3.3.3.3 Fibromyalgia and physical activity 
According to general advice for prevention of MSDs, varied PA has a well-documented 
preventive effect for MSDs, including FM (2). Obtaining the diagnosis of FM has demonstrated 
an association with low levels of PA. This was despite the fact that increased PA had been 
demonstrated to reduce pain and improve quality of life in these patients (13, 65). Premorbid 
levels of PA and the association with developing FM have not been well explored in literature. 
The previously mentioned case-control study by Smith et al. suggested a high premorbid pattern 
of PA for those participants that developed FM (41). It must be reiterated that their study had 
problems with statistical power. FM patients also report that experienced pain prevents them 
from being as physically active as recommended. The same patients are most frequently seen to 
be physically inactive (13). Women report lower levels of physical fitness, but do not report 
lower levels of PA (2). According to Lærum et al., women with FM also reported that PA 
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increased pain and exhaustion more to a larger extent than healthy women (2).  
 
3.3.4 Muscle pain/myalgia 
The outcome reporting item of muscle pain/myalgia was the outcome included in our study 
which had the most room for individual interpretation. Asking a lay person to define what 
‘muscle pain’ is, might possibly gather as many answers as persons asked. Even in clinic, muscle 
pain is a broad category to diagnose (66). There are several possible sub-categories of muscle 
pain disorders which frequently overlap, causing diffuse and indistinct boarders of definitions. It 
was not clear from the item in the questionnaire what muscle pain referred to, as no definition 
was given for respondents to align themselves to. We therefore looked at some broad terms used 
in clinic to describe muscle pain conditions in an attempt to demonstrate the variation inherent in 
the term ‘muscle pain’ for purposes of discussion. However, it must be kept in mind that no such 
clarification was offered to respondents in the NOWAC study.  
 
Frequently used terms for muscle pain both within clinic and literature include myalgia, 
myofascial pain, myofascial pain syndrome, muscle soreness, delayed onset muscle soreness, 
myofascial trigger points, regional soft tissue pain, and localized muscle pain, amongst others 
(39, 66-70). Causes for these types of muscle pain are almost as diverse as the terminology itself.  
Literature often uses the terms myalgia and myofascial pain interchangeably to describe localized 
muscle pain, although ICD 10 employs the former (39). Parfitt et al. defined myalgia as “acute, 
local, noninflammatory pain” in musculature (69). The term is thus often used to describe a 
localized pain condition in musculature that can have a number of causes but usually follows an 
approximately similar pattern of manifestation. Myofascial pain, also referred to in clinic as 
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“regional soft tissue pain” (66), is pain which comes from muscles or their fascia (67). Myalgia 
often presents with localized pain in the form of muscle “foci”, giving rise to a feeling of stiffness 
in the area in combination with a deep aching sensation which is aggravated by using the affected 
muscles (67). The presence of “foci” (or myofascial triggerpoints) has previously been a 
presumption for the diagnosis, although no sufficiently validated diagnostic criteria for 
identifying trigger points have been developed (67). Bennett reported that such muscular pain 
was often caused by overuse, repetitive strain or acute muscle injury (67). Borg-Stein and Simons 
also reported that onset may follow an incident of trauma or injury, or appear more gradually 
(71). They can also be of an infectious nature, or be caused by medication use (68), but appears to 
be most often used as a differential term for conditions of non-traumatic, non-infectious and non-
pathogenic origin. Localized muscle pain problems can be temporary, although some authors 
reported the tendency of lasting pain to develop into what was termed “myofascial pain 
syndrome” (67). Borg-Stein reported myofascial pain syndrome to be a condition characterized 
by pain arising from several myofascial trigger points in possible tandem with other pain 
generators, thereby indicating a condition that might be more widespread than single localized 
muscle pains (66). Brukner and Khan referred to this as a common local pain disorder (70).  
 
The pathophysiological causes behind localized myofascial pain are still not fully understood 
(67). In clinic, the most important step is to identify possible underlying morbidity for the 
symptom of myalgia (68). Schmerling attempted to divide myalgia into groups on basis of 
suspected etiology: myalgia with diffuse or localized symptoms. Conditions causing the diffuse 
variants were listed as “systemic rheumatic disease, fibromyalgia, infection, medication use, 
metabolic derangements, hypothyroidism, psychiatric causes”, while localized myalgia were 
theorized to be caused by “strenuous activity, soft tissue disease, pyomyositis, myofascial pain 
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syndrome, muscle infarction, and compartment syndrome” (68). The author thus included 
conditions beyond the narrow types of “localized muscle pain” in the attempt to chart possible 
causes (68).  
 
The discrimination between individuals with myalgia and FM is not overly good (67), but the 
important difference is the absence of a global pattern of widespread pain, fatigue and sleep 
disturbance in myalgia (71). This difference in distribution of muscle pain gives cause to say that 
myalgia can be a condition separate from those of CFS, FM and diffuse BP. However, it is also 
clear that patients with chronic pain conditions may report myalgia as a symptom of their 
condition. Borg-Stein reported that women and men had the same prevalence rates of myofascial 
pain (66). 
 
Based on these diverse definitions and proposed causes of muscle pain conditions, we expected 
muscle pain in some form or other to occur regardless of level of PA. Possibly some causations 
will be more common with certain levels of PA than others, such as muscle pain due to delayed 
onset muscle soreness after activity in people with lower PA groups (70). The diversity of muscle 
pain conditions and causes implies that all individuals are prone to experience a form of this 
phenomenon at some point or points during life.  
 
In conclusion, what respondents were referring to when returning information on “muscle 
pain/myalgia” might include a variety of causes and conditions. The term “muscle pain” appears 
to be too broad for useful registering of one discrete condition, as respondents might be thinking 
of any number of the conditions described above when reporting this - there is no guarantee for 
how respondents choose to interpret the questionnaire item. This might question the usefulness of 
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“muscle pain/myalgia” as an outcome measurement, but the fact remains that however they 
wished to define it, respondents in the NOWAC study were reporting this phenomenon. We 
therefore chose to explore the available data.  
 
3.3.5 Overlap of chronic fatigue syndrome and fibromyalgia 
It is evident that there is a substantial overlap of these two conditions. Patients are at risk of being 
diagnosed to either one when presenting with symptoms that are common for both, such as 
fatigue and musculoskeletal pain. Perhaps one of the main differences is the gravity of either of 
these two symptoms, with those experiencing the most pain being categorized as FM, and vice 
versa. Due to their similarity, some have suggested combining the two conditions: 
“Van Houdenhove (2003) even concluded that there is preliminary evidence for a 
relationship between CFS/FM and complex regional pain syndrome type I, based on many 
clinical features similar with CFS and FM, such as a predominance in women, frequent 
traumatic onset and allodynia or hyperalgesia.” (19) 
 
Both conditions were included as separate outcomes in our study. Similar associations between 
these two outcomes and PA might strengthen the suggestions of Van Houdenhove.   
 
3.4 Covariates 
The following are covariates as reported by respondents in the study. Possible association with 
PA and the outcomes we were looking for is examined in further detail below.  
 
3.4.1 Age 
Taffet reported on broadly predictable changes brought on by ageing that were associated with an 
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increased susceptibility to many diseases. This effect was modified by factors such as genetics, 
lifestyle, and exposure through the environment (72). Age has been found to be a risk factor for 
some chronic pain conditions (13). It has been reported that musculoskeletal pain is most 
frequently present in the age group 40-60 years (2). Deyo reported BP to be more frequent in the 
age group above 45, but also stated that it became less prevalent among the oldest participants 
(52). Dionne et al. reported a similar curvilinear trend for BP of benign and mixed causes 
according to age groups (51).  
 
PA is now recognized as a crucial element in maintaining health  among older adults while 
reducing their risk of developing a number of chronic conditions (73). Dumith et al. found 
prevalence of inactivity to be greatest in women and to increase by age (25). However Norwegian 
numbers from 2008-2009 indicated that women and men were not significantly different with 
regards to physical inactivity (74), except for groups aged 70 and above, which were significantly 
more inactive than younger age groups.  
 
3.4.2 Body mass index  
Like ageing, increasing body mass index (BMI) is also recognized as a risk factor for much of 
morbidity and mortality. The WHO states that:  
“Mortality rates increase with increasing degrees of overweight, as measured by 
BMI. To achieve optimal health, the median BMI for adult populations should be 
in the range of 21 to 23 kg/m2, while the goal for individuals should be to 
maintain a BMI in the range 18.5 to 24.9 kg/m2, and moderate to severe risk of 
co-morbidities for a BMI greater than 30 kg/m2. There is increased risk of co-
morbidities for BMIs in the range of 25.0 to 29.9 kg/m2” (5) 
 
1 in 5 Norwegians were reported to be obese in 2011. There was no significant difference 
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between genders, except for a female dominance in the older age groups (75). Senie reported an 
increasing pattern of chronic diseases corresponding to the rapid rise of obesity of human 
populations during the recent decades (53).  
 
Obesity and PA are correlated to each other. Increased physical inactivity causes increased BMI 
and prevalence of obesity, and obesity in itself can be a factor limiting level of PA due to 
motivational and exertional difficulties (76). Shiri et al. observed that leisure time PA decreased 
with obesity, which again increased the risk of BP. Thus, PA is important to individuals who are 
obese or overweight in order to prevent BP (10). Shiri et al. found that obesity but not excess 
weight increased the risk of radiating BP (10). The effect of abdominal obesity for this condition 
was seen in women in particular (10). There seemed to be a difference in magnitude of risk 
between overweight and obesity. Of the other three outcomes in our study, the link between 
increased BMI and disease is not well understood, but on a general basis it has been suggested 
that higher levels of BMI – possibly obesity – is a risk factor for MSDs (75). 
 
There exists some controversy surrounding the association between BMI and morbidity. Janssen 
et al. stated that it was waist circumference, and not BMI in itself, that explained the health risk in 
obesity (77). BMI as a measure does not differentiate between body tissue composition, but only 
the ratio of weight and height. Overweight and obesity on the other hand are descriptions of an 
unhealthy body composition consisting of excess body fat. Shiri et al. reported that waist 
circumference may be a better measure of obesity compared to BMI (10).  
3.4.3 Education 
Education is a social determinant of health, both in form of what knowledge an individual has 
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access to and the possibility of understanding and applying it, but more importantly by the way it 
gives access to occupation and salary, and the lifestyle associated with these. As a social 
determinant of health, a lack of education has proven to be a risk factor for mortality and 
morbidity (5). Frydenberg et al. found that MSDs were less prevalent among persons with higher 
education, compared to those of lower education levels (78). Explanations included less physical 
straining work in higher education occupations, and possible lifestyle differences between lower 
and higher educated persons (78). Higher education was inversely associated with prevalence of 
BP (2). Prins et al. reported a higher prevalence of CFS in adults with lower education (35).  
 
In Norway, shorter lengths of education was associated with inactivity; the shorter the length of 
education, the less leisure time the person was likely to spend on PA (79). Studies on the 
Norwegian population in 2012, reported 18% of those with lowest education levels to be inactive, 
compared to only 6% of those with the highest (26). 
 
3.4.4 Alcohol 
Alcohol overuse is one of the major risk factors for non-communicable diseases (5). There is 
little theory indicating that alcohol exposure is a risk factor for MSDs. Moderate alcohol intake 
has in some cases been shown to reduce the risk of ischemic heart disease (80). Association 
between alcohol consumption and morbidity is complex and dependent on both pattern of, as well 





Cigarette smoking remains one of the most important modifiable risk factors for chronic disease 
today, along with physical inactivity (31). There are currently 1.3 billion smokers, most of which 
live in developing countries (81). Smoking as a social determinant of health also displays 
variation in prevalence within population subgroups. Lower socioeconomic groups have a higher 
prevalence of smoking (31). The WHO reported that higher levels of daily smoking was found to 
be associated with lower levels of educations (5). Smoking is also a risk factor for experiencing 
acute myocardial infarction, cancer, and diabetes (81, 82). 
 
There is an association between cigarette smoking and risk of muscle pain (83). Independently of 
confounding factors, early disability pension due to musculoskeletal conditions and low back 
diagnoses was associated with persistent smoking (84). Reports indicated daily smoking to be a 
risk factor for onset of severe BP (15, 85). Two early epidemiologic studies in Norway reported 
that smoking was associated with increased levels of musculoskeletal pain (86, 87). Eriksen et al. 
reported that young and middle-aged persons who smoked experienced more and worse pain 
when they smoked compared to when they did not (75).  
 
The majority or articles included in a meta-analysis on smoking and levels of PA indicated that 
smoking and PA are inversely related – more smoking led to less PA (31). Kaczynski et al. 
reported finding some weak evidence that smoking was associated with lower levels of PA in 
women (31). Early reports by Conway and Cronan found that current smokers engaged in less 





Respondents in the NOWAC study reported on some sets of other morbidities, including diabetes 
and ischemic heart disease (IHD). Cancer data was gathered from the Norwegian Cancer 




There are primarily two types of diabetes – type 1 and 2. Of these, 80-90% is type 2, which is 
dependent upon a genetic susceptibility (89). Risk factors for diabetes 2 include physical 
inactivity, smoking and obesity. This causes the disease often to be referred to as the lifestyle-
induced type (89). Prevalence of known type 2 diabetes among Norwegian women was reported 
at 3.5-4% in 2007-2008 (90). Health authorities presume the prevalence of unknown type 2 
diabetes to be approximately the same. Diabetes is a risk factor for IHD, especially among 
women (90).  
 
MSDs have been reported to occur more frequently in diabetes patients (91). Cagliero et al. 
reported MSDs to be present in almost 40% of diabetic patients (92). However, this group of 
conditions, as we have seen, is quite diverse. Diabetes, type 2 mellitus in particular, affects the 
connective tissues in the body (92, 93). As such, several comorbidities often occur alongside it. 
These include a number of joint and skeletal disorders (80) of local and known origin. These 
types of conditions are not marked by the sort of global, diffuse patterns as those of interest to our 
study, and diabetes has not been explicitly reported as a risk factor for these types of MSDs. 
However, regional musculoskeletal disease can possibly exacerbate patterns of global 
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musculoskeletal pain, in which case diabetes can be thought of as an indirect risk factor for 
developing diffuse MSDs like the outcomes of our study. Furthermore, Abate et al. suggested the 
presence of a subclinical, low-grade systemic inflammation state in conditions of obesity and 
metabolic disorders (94). In addition to affecting the musculoskeletal apparatus, it could be 
theorized that such a systemic state might exacerbate diffuse, global musculoskeletal ailments.  
 
Diabetes has been shown to be associated with physical inactivity, with an adjusted relative risk 
of 1.20 for being inactive if diabetes is present (7). Exercise as diabetes treatment is considered 
one of the cornerstones in an optimal treatment regime (95).   
 
3.5.2 Cancer 
Cancers are one of the leading causes of mortality in the non-communicable disease group (5). 
The causes of cancer are many and consist of an interaction between genetics, lifestyle habits and 
the environment (96). Risky lifestyle factors include previously mentioned smoking, obesity, 
alcohol, and physical inactivity (5). Inactivity and obesity have been shown to increase the risk of 
several types of cancer by as much as 25% (5), and especially colon and breast cancer (7). 
Norwegian women have a slightly lower prevalence of total cancers than men (54.1% versus 
45.9%) (97). When measured in five-year periods, cancer incidence in Norwegian women had 
risen by 2% by the end of 2011 (97).   
 
Cancer in the musculoskeletal system is liable to be a cause for musculoskeletal pain/myalgia and 
disability. However, only 1% of all musculoskeletal pain reported in Norway was cancer-related 
(2). Cancer is an exclusion criterion for a diagnosis of CFS (35, 36) – in some cases symptoms 
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can be of a similar nature. It is also an exclusion criterion for BP, according to already established 
definitions. FM is a diagnosis of exclusion, when  inflammation or damage are not present to 
explain the widespread pain (98), and as such should not be diagnosed in tandem with a cancer 
diagnosis. Cancer does not appear to be mentioned specifically as a precipitating factor for our 
four outcome conditions.  
 
3.5.3 Ischemic heart disease 
IHD was reported in the questionnaires of the NOWAC study by questions of angina and 
myocardial infarction (MI) status. Physical inactivity is a strong predictor for coronary heart 
disease (99), in addition to other previously described lifestyle habits. Raised blood pressure is an 
important risk factor for developing cardiovascular disease (5). IHD follows typical patterns of 
socioeconomic status, with conditions occurring more often and impacting more severely in low-
resource settings (5). 
 
High blood pressure is a demonstrated risk factor for BP (50). Furthermore, psychosocial stress 
can be a risk factor for chronic widespread pain, and high blood pressure might function as a 
symptom of such stress. The literature does not draw clear links between IHD and the MSDs 
serving as outcomes in our study. However, IHD follows the same distribution in society as the 
other typical risk factors for MSDs. This contributes to create a possible picture of the person at 
risk for these conditions. 
 
Keeping all this theory in mind, we now move on to assess the association between levels of PA 







4. Materials and methods 
We planned and performed a prospective cohort study based on data from the NOWAC study. 
Information regarding the NOWAC study and its participants was obtained from the NOWAC 
study homepage on the internet, as well as articles describing the cohort (100-105). 
 
4.1 The Norwegian Women and Cancer study 
All data material used in our study was gathered from the NOWAC study, headed by the 
Department of Community Medicine at The Arctic University of Norway, University of Tromsø. 
The NOWAC study is a longitudinal cohort study originally started in 1991 to investigate 
possible associations between internal and external hormones and female cancer (100). Data were 
obtained through self-administered questionnaires which participants receive per mail. All 
women born between 1921-1961 were sampled randomly from the Norwegian Central Person 
Register which contains information on all Norwegian inhabitants including a unique birth-
number which consists of a date of birth and five individualized personal numbers and personal 
numbers (100).  
 
4.1.1 Questionnaires in the Norwegian Women and Cancer study 
Participants in the NOWAC study were invited to attend the initial round of questionnaires, with 
the possibility to be contacted at later occasions for further follow-up. At the present time there 
exists one baseline and two follow-up rounds of questionnaires. Each round was separated by 4-8 
years of follow-up time. Several series of questionnaires (2-8 pages long) were developed and 
sent to participants, most containing questions on diet, exogenous hormone use, other diseases, 
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reproductive information, smoking habits, and alcohol consumption. Information on cancer status 
was then linked to participants from the Norwegian Cancer Registry. All series of questionnaires 
asked for self-reported PA. Many series also asked for information on prevalence and incidence 
of the MSDs serving as outcome measurements in our study: CFS, BP, FM, and myalgia. Some 
series were developed as part of validation studies, with questions differing somewhat in 
accordance with the nature of such studies. Some series were shorter forms, focusing only on 
such things as cancer and exogenous hormone use, or cancer and diet.  
 
4.1.2 Participants and follow-up in the Norwegian Women and Cancer study 
Baseline invitations were performed during the years 1991-1997. 102 540 women aged 30-70 
years returned filled-in questionnaires, a total of 57%. An expansion of the cohort with 60 000 
new invites was performed during the years 2003-2004, returning 27 400 filled-in questionnaires 
by women aged 45-60 years. An additional expansion was done during 2007, inviting another 
88 000 women, of whom 42 600 – 48.4% - returned a filled-in questionnaire. 
 
The first follow-up began in 1998 and continued through 2002. During this time, 80 693 women 
returned a filled-in questionnaire, yielding a response rate of 81%. The second follow-up was 
done during 2004-2005. A total of 47 586 filled-in questionnaires were returned. Figure 4.1 
displays the different series of questionnaires and the rounds of follow-up to which they belong, 





Figure 4.1: Cohort enrolment in the NOWAC study: participants, questionnaires, and baseline/follow-ups (101). 
 
4.2 Inclusion and exclusion in present study 
For the present study, only questionnaire series from the NOWAC study containing relevant 
baseline exposure levels of PA, and follow-up endpoint information on MSDs, were included. 
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This caused data material for our study to be obtained from baseline, series 1-5, 8-16, 19-24, 35; 
first follow-up, series 25-29, 32-33, 47; and second follow-up, series 38-39, 42, 46. Figure 4.2 
displays the flow of participants eligible for our study produced by those series that contained 
relevant data on exposure and outcome.   
 
Figure 4.2: Flow chart of participants in present study. 
 
Out of the present total invited participants of 196 387 women, all those who responded on 
baseline and follow-ups totaled 83 415 respondents. Inclusion criteria for our study was reporting 
on PA at baseline. This gave a final study sample of 76 367 women with information from 
baseline and follow-up. These were the women returning information on PA at baseline, as well 
as returning questionnaires containing questions about the four outcomes during follow-up. 
Characteristics of participants, including their reported level of PA at enrolment, were obtained 




There was a drop-out of included participants between the first and second follow-up. Of 
participants responding to first follow-up, 46% did not respond to the second follow-up.  
 
Exclusion criteria for analysis were set according to outcome status. As cumulative incidence 
during the study period was the outcome of interest, prevalent cases at the time of enrolment were 
excluded from the corresponding analysis of that outcome.  
 
4.3 Analysis of data 
The following outlines how variables were gathered and coded from the NOWAC study and what 
statistical methods were used to assess the information.  
 
4.3.1 Exposure and outcomes in the material 
When measuring PA in large populations, it can be acceptable to use different kinds of survey on 
grounds of practicality, feasibility and economics (24). Reports must be converted into a 
measurement metrics that allows ranking of degree of PA according to each other (24). In our 
study, PA was measured per self-reporting in a questionnaire. See appendix A for an example 
questionnaire from the NOWAC study. 
 
4.3.1.1 Physical activity measurement 
The exposure variable for level of PA was obtained from a ten-point scale included in the original 
questionnaires. Participants were asked to “indicate your level of physical activity on a scale from 
‘very low’ to ‘very high’. The scale below runs from 1-10. By physical activity is meant both work 
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in the home as well as occupational activity, exercise, and other forms of physical activity such 
as taking walks, hikes, and so forth. Indicate that number which best represents your level of 
physical activity” (figure 4.3). PA level existed in the data set as a ten-point variable but was 
recoded into a five-category variable as preparation for analysis. Reported levels 1-2 were coded 
as “very low”, levels 3-4 were coded as “low”, levels 5-6 were coded as “moderate”, levels 7-8 
were coded as “high”, and levels 9-10 were coded as “very high”. Category “moderate” was used 
as reference group in logistic regression analysis. This manner of recoding PA has previously 
been demonstrated on the same dataset and appears to be a functional manner of preparing the 
variable for logistic regression analysis (106, 107). Due to the reporting that moderate PA might 
be more protective for MSDs than high and low levels of PA, the moderate group was used as 
reference category in the logistic regression model for BP. This was also the largest of the 
groups, and therefore served well as a reference group.  
 
Figure 4.3: Example of reporting item on physical activity from NOWAC questionnaire. 
 
4.3.1.2 Outcome measures 
Outcome variables were included in the questionnaire under the following description: “For the 
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following conditions, tick off the box for which year the condition arose or report the year of the 
period before [study period start]”. Selectable options included boxes for all the years of the 
period including one marked “before the year [study period start]”. This allowed the onsets of the 
diseases to be assessed, and the production of four different outcome-variables coded “no”, 
“incidence” and “prevalence”, with prevalence defined as all cases in the years before baseline. 
Based on these, participants with prevalence could be censored in logistic regression analysis. 
 
4.3.2 Confounders 
Confounders in the study as previously discussed were deemed of importance to the outcomes at 
hand and included in statistical modeling to assess their confounding effect on the association 
between levels of PA and the outcomes: 
 
Age at enrolment was derived from respondents’ year of birth. Age was recoded into age groups 
of 10 units per group, giving a total of five groups: 30-39, 40-49 , 50-59, 60-69, and 70-79. The 
final two age groups, 60-69 and 70-79, were combined as the oldest enrolled participants were 70 
years of age and few in numbers. The reference category of age was set to the second level, 40-49 
years.  
 
BMI at enrolment was calculated from respondents’ specification of current height and weight. 
BMI was recoded into the following categories in accordance with the WHO classification of 
BMI: “normal weight (BMI = 18.5-24.99)”; “underweight (BMI < 18.5)”; “overweight (BMI = 
25-29.99)” and “obese (BMI ≥ 30)” (108). The category for normal weight was used as reference 
category in logistic regression analysis. 
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Length of education was obtained by asking participants about their total length of education or 
vocational training. Education was grouped as following: “0-9 years”, “10-12 years” and “≥ 13 
years”. Category 1 was used as reference category in logistic regression analysis. 
 
Alcohol consumption was recorded by asking participants whether they were completely 
abstinent, or if not then how often they consumed one unit of beer (½ liter), wine (1 glass) or 
spirits (drinks), on average during the last year. Options included “never/seldom”, “1 per month”, 
“2-3 per month”, “1 per week”, “2-4 per week”, “5-6 per week” and “1+ per day”. Consumption 
was then calculated into grams per day. The data was recoded into four groups: “0.1-3.9 grams 
per day”, “complete abstinence”, “4-10 grams per day” and “> 10 grams per day”. Category “0.1-
3.9” was used as reference category in logistic regression analysis. 
 
Smoking was registered by asking if they were current smokers. Our study used the variable 
displaying current smoking status, coded as “never”, “former” and “current”. Category “never” 
was used as reference category in logistic regression analysis. The first 10 series of 
questionnaires in the NOWAC study did not ask about current smoking habits, but derived this 
from respondents reporting how many cigarettes they were currently smoking per day. 
 
Diabetes at enrolment was reported by participants in response to being asked “Have you had any 
of the following diseases” and being prompted to report starting age if they had. This allowed for 
coding of diabetes as a dichotomous “no/yes” prevalence variable for inclusion in logistic 
regression analysis.  
 
Cancer was not included as a question in the original baseline series as NOWAC is linked 
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directly to the cancer registries. Cancer status for participants was obtained directly from the 
National Cancer Registry. Any type of cancer present in history was coded into a dichotomous 
“no/yes” prevalence variable for inclusion in logistic regression analysis. 
 
Ischemic heart disease was combined from respondents’ reporting of present angina or 
myocardial infarction in the same dimension as diabetes. These were combined to create a 
dichotomous “no/yes” IHD variable to determine prevalence at baseline, for inclusion in logistic 
regression analysis.  
 
4.4 Statistical methods 
The following outlines the statistical methods used to assess the data gathered from the NOWAC 
study. This included both the descriptive statistics used to gain an overview of the distribution of 
variables within the selection, and the logistic regression analysis used to assess the association 
between exposure and outcomes. 
 
4.4.1 Descriptive statistics 
Descriptive statistics were used to obtain information on the study participants. Means and 
standard deviations were used to assess the dispersion of data, or median and percentiles if data 
were asymmetrically spread or prone to outliers. Groups were compared and trends were tested 
using ANOVA for continuous variables. For ordinal or nominal variables, the non-parametric 
Kruskal-Wallis test was used to compare groups. Variables were grouped according to levels of 
PA, to more easily compare the groups of exposure in relations to each other. 
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We calculated an incidence rate for all four outcomes. The entire cohort was divided into 4 sub 
cohorts in order to estimate the person-time between the different questionnaire series from 
baseline through second follow-up. This was done because the different sub cohorts had different 
follow-up times. Case accumulation was assumed to occur at a constant rate during the years of 
follow-up. All participants not experiencing the outcome accounted for as many years of person 
time as there were follow-up years. Total person-time was summed for all sub cohorts, and 
number of incident cases divided by it in order to obtain incidence rate for each outcome. 
Incidence rate was reported per 100 000 person-years.  
 
Prevalent cases were reported for each outcome. In order to make rates more easily applicable to 
the mother population, prevalence rates were then age standardized using direct standardization 
based on 2013 numbers of corresponding age groups for the female population of Norway, 
gathered from Statistics Norway (109). We also reported prevalence rates for all four outcomes, 
as rates per 100 000. Since prevalence rates were based on reporting from baseline measurements 
performed during several different time periods between 1991-2003, they are aggregate rates for 
all of the periods. We note that our sample included age groups 30-70. Mean age of participants 
at enrolment was reported for each outcome. 
 
4.4.2 Logistic regression models 
All statistical analysis was performed using IBM SPSS Statistics v. 21 for Windows. Microsoft 
Excel 2010 for Windows was used for creating tables and figures of results.  
Initially a cox proportional hazard regression was considered, but deemed unfit due to 
inconsistencies in reporting of time at onset of disease between first and second follow-up. 
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Logistic regression was selected as the main method of analyzing the strength of association due 
to the dichotomous nature of the outcomes of interest (110). This would also allow controlling for 
possible confounders. Four logistic regression models were made, one with each of the four 
different outcomes as the dependent variable: CFS, BP, FM, and myalgia. Prevalent cases were 
excluded for the one diagnose examined as endpoint in each of the four models. Acceptable alpha 
level was set to 5%. Linear trend of PA was reported first, before categorical comparison of PA 
levels was performed. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported. 
Hosmer-Lemeshow tests were done to assess the goodness-of-fit of the model. 
 
Univariate analysis of covariates against each of the four outcomes was performed preliminary. 
This was done to assess the predictive power of the covariates for outcomes. Significant variables 
were then included one by one in building a model for each outcome. Insignificant variables were 
finally added to the model to check for new significance levels. A correlation matrix was then 
created to assess the correlation levels between PA and confounders. All such predictors that 
were significant and also correlated to PA were to be further assessed as possible confounders to 
be adjusted for in the final model. When building the final models, covariates that had a 
confounding effect of a certain magnitude on the main estimate of association were included. The 
level of confounding deemed necessary for a covariate to be included was set at 5%. 
Confounding was determined comparing age-adjusted ORs for PA to ORs for PA when including 
each of the covariates separately. If ORs changed by 5% or more for any of the PA level 
associations with the outcomes, the covariate was considered to have a confounding effect on the 
association between PA and the outcomes, and was subsequently included in the final model. In 
cases of doubt, when several levels lay close to but below the 5% level, we chose to include the 
covariate on basis of previously described theoretical knowledge. If a covariate was found to be a 
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confounder for the association to one of the outcomes, it was included in all four models. In the 
end, based on assessment of confounders as well as theory, we ended up with four identical 
models containing age, as well as the following lifestyle factors: BMI, education levels, alcohol 
consumption, and smoking. Of these, smoking was the only variable not reaching the 5% 
confounding level, but was included in analysis nevertheless based on previous knowledge that 
smoking and levels of PA are closely related. 
 
Sensitivity analysis was performed in order to assess what effect including participants with one 
or several comorbidities would have on the ORs of PA. These comorbidities were diabetes, 
cancer and IHD. We ran analysis of the main models while including a filter that removed 
participants with each of the comorbidities. Persons with comorbidities were excluded first 
separately for each condition, and then together, and ORs of PA compared. The differences in 
ORs were compared using Wald statistics. No significant differences were found and therefore 
comorbidity covariates were left out of the model. 
 
4.4.2.2 Missing in analysis 
In order to censor prevalent cases of each of the four outcomes, values corresponding to 
prevalence were set to system missing. This caused a proportion of cases to be missing in each of 
the four models equal to the proportion of prevalence for each of the four outcomes. Additional 
cases became missing when all adjustment variables were included in the models, due to non-
item reply for respondents on some of these. Proportion of excluded cases due to prevalence and 




Table 4.1 Proportion missing cases in analysis due to prevalent cases of chronic fatigue syndrome (CFS), back pain 
(BP), fibromyalgia (FM) and myalgia, as well as for non-item response: 
 CFS BP FM Myalgia 
Excluded prevalent cases: 





























This chapter presents all descriptive and analytical results from statistical analysis of the data. 
5.1 Descriptive statistics of data 
Descriptive data in our selection was divided in distribution of outcome variables, and 
distribution of other covariates in the selection. 
 
5.1.1 Descriptive statistics of outcomes 
Table 5.1 reports the distribution of the main outcomes of interest among the participants, 
grouped by reported levels of PA.  
 
Total number of incident and prevalent cases, as well as prevalence rates and age standardized 
prevalence rates for each outcome, is reported in table 5.1. Mean age for the four outcomes were 
as follows: For CFS, 48.6 (standard deviation (sd) 8.2) years; for BP, 48.3 (sd 8.6) years; for FM, 
49.1 (sd 7.9) years; for myalgia, 48.3 (sd 8.3) years. These averages were slightly higher than 
mean age of the entire sample, at 46.9 years. Reported prevalence rates are valid for populations 
of this mean age respectively for each outcome.  
 
PA levels at baseline were distributed as follows: Very low = 5.1%; low = 21.1%; moderate = 
41.9%; high = 25.4%; very high = 6.6%, totaling 76367 participants. This appeared to be 





Figure 5.1 Number of respondents within each physical activity (PA) group. Normal distribution curve is displayed. 
 
 
Chronic fatigue syndrome:  
The incidence rate for CFS was 411 per 100 000 person-years. There were 3229 new cases during 
follow-up, 4.2% of the sample. 2.58% reported prevalent CFS at enrolment, quite similar to the 
age standardized prevalence of 2.62%. Prevalent cases were excluded from analysis when CFS 
was the outcome. Incidence followed an apparently normally distributed pattern across PA 
groups due to the magnitude of the group size as seen in table 5.1. However, the relative 
incidence of CFS within each PA group was as follows: Very low = 6.6%; low = 4.9%; moderate 
= 3.9%; high = 3.7%; very high = 4.6%, as seen in figure 5.2.  
 
Back pain:  
Incidence rate for BP was calculated to be 1268 per 100 000 person-years. The total number of 
incident cases of reported BP was 8353, 10.9% of the sample, during the follow-up time. 13.65% 
reported prevalent BP at enrolment, as compared to the age standardized rate of 14.22%. 
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followed an apparently normally distributed pattern across PA groups due to the magnitude of the 
group size. However, the relative incidence of BP within each PA group was as follows: Very 




The incidence rate of FM was calculated to be 287 per 100 000 person-years. Number of new 
cases of reported FM was 2194, 2.9% of the sample. 5.02% of the sample reported prevalent FM 
at enrolment, quite similar to the age standardized prevalence rate 5.03%. Prevalent cases were 
excluded from analysis when FM was the outcome. Incidence followed an apparently normally 
distributed pattern across PA groups due to the magnitude of the group size. However, the 
relative incidence of FM within each PA group was as follows: Very low = 3.7%; low = 3%; 
moderate = 2.8%; high = 2.6%; very high = 3%, as seen in figure 5.2.  
  
Myalgia:  
Finally, incidence rate for myalgia was calculated to be 1509 per 100 000 person-years. The total 
number of new cases of reported myalgia was 9363, 12.3% of the sample. 17.87% reported 
prevalent myalgia at enrolment into the NOWAC study. Age standardized prevalence rate was 
18.09%, which was quite close. Prevalent cases were again excluded from analysis when myalgia 
was the outcome. Incidence followed an apparently normally distributed pattern across PA 
groups due to the magnitude of the group size. The relative incidence of myalgia within each PA 
group was as follows: Very low = 12.8%; low = 12.2%; moderate = 12.3%; high = 12.1%; very 




The patterns of total and relative incidence were quite similar for all four diagnoses. Common for 
all diagnoses were dropping incidence levels from PA group “very low” to group “high”, with a 
late increase in incidence from group “high” to group “very high”. With CFS, incidence level for 
group “very high” was higher than for group “moderate”. For BP, incidence level for group “very 
high” was identical to that of group “moderate”. For FM, incidence level for group “very high” 
was identical to that of group “low”. For myalgia, incidence level for group “very high” was 
identical to that of group “very low” and the highest of all the groups. As with incidence, BP and 
myalgia had the highest rates of prevalence compared to the other two. Mean age in prevalent 
cases was higher for all four outcomes than for the study sample as a whole. SDs of mean age in 
prevalent cases suggested that most prevalent cases (95% CI) were approximately between 32 
and 64 years of age. 
 
 





























Table 5.1 Distribution of incidence and prevalence for outcomes, and across physical activity (PA) groups: 
PA group: Total(proportion): Very low Low Moderate High Very high 
Group total n = 76367 (100%) 3869 (5.1%) 16104 (21.1%) 31968 (41.9%) 19413 (25.4%) 5013 (6.6%) 
 
Chronic fatigue syndrome: 
      
Proportion incidence within PA group 3229 (4.23%) 6.6 % 4.9 % 3.9 % 3.7 % 4.6 % 
Incidence rate  
(per 100 000 person-years) 
411.41      
Prevalence 1968 (2.58%)      
Age standardized prevalence 2.62%      
 
Back pain: 
      
Proportion incidence within PA group 8353 (10.94%) 11.8 % 11.3 % 11.0 % 10.3 % 11.0 % 
Incidence rate 
(per 100 000 person-years) 
1267.85      
Prevalence 10422 (13.65%)      
Age standardized prevalence 14.22%      
 
Fibromyalgia: 
      
Proportion incidence within PA group 2194 (2.87%) 3.7 % 3.0 % 2.8 % 2.6 % 3.0 % 
Incidence rate 
(per 100 000 person-years) 
287.06      
Prevalence 3837 (5.02%)      
Age standardized prevalence 5.03%      
 
Myalgia: 
      
Proportion incidence within PA group 9363 (12.26%) 12.8 % 12.2 % 12.3 % 12.1 % 12.8 % 
Incidence rate 
(per 100 000 person-years) 
1509.14      
Prevalence 13649 (17.87%)      
Age standardized prevalence 18.09%      
 
Total cases incidence+prevalence 
 
56616 
     
 
 
5.1.1.1 Combination of outcome conditions in participants 
Table 5.2 displays the different combinations of outcomes that appeared in participants, both 
prevalent and incident cases. Each category is exclusive, meaning no participant could be in more 
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than one category at the same time. CFS appeared 1015 times by itself, and 4182 times in 
combination with one or more other conditions. BP appeared 7236 times by itself, and 11539 
times in combination with one or more other conditions. FM appeared 988 times by itself, and 
5043 times in combination with one or more other conditions. Myalgia appeared by itself 9495 
times, and 13517 times in combination with one or more other conditions. Both CFS and FM 
appeared to occur less frequently alone than they did in combination with other conditions. Both 
myalgia and BP appeared to occur frequently both alone and in combination with other 
conditions.  
 
CFS and FM appeared exclusively together only in 90 respondents. However, they appeared 
together in 1347 respondents alongside additional conditions. 
 
















M-F 1512 2.0 
M-CFS 1042 1.4 
M-BP 6761 8.9 
F-CFS 90 .1 
F-BP 445 .6 
CFS-BP 423 .6 
M-CFS-BP 1280 1.7 
M-F-BP 1649 2.2 
M-F-CFS 366 .5 
F-CFS-BP 74 .1 
M-F-CFS-BP 907 1.2 
Healthy 43084 56.4 
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Figure 5.3 Proportion of participants having 0, 1, 2, 3, and 4 simultaneous outcome conditions. 
 
5.1.2 Descriptive statistics of study population 
Mean follow-up time between baseline and first follow-up was 6.4 years. Mean follow-up time 
between first follow-up and second follow-up was 6.7 years. For the time interval between 
baseline and second follow-up, the mean follow-up time was 13.1 years. Max follow up time was 
15 years. 
 
The distribution of covariates according to levels of PA is reported in table 5.3.  
 
Maximum age at enrolment was 70 years, minimum was 34. Mean age was 46.9 (sd 8.4). Age 
differed significantly between groups of PA (p< 0.001). Test for linear trend was also significant 
(p< 0.001) and indicated a trend of decreasing age with increased PA. Participants registering at 
“very low” activity level were 47.8 years of age on average, and participants reporting a “very 
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on the age-item, as birth year was obtained from the Norwegian Central Person Register.  
 
Maximum BMI registered at enrolment was 69.5 and minimum was 12. Mean BMI among 
respondents was 23.6 (sd 3.6). BMI differed significantly between groups of PA (p< 0.001). Test 
for linear trend was also significant (p< 0.001) and indicated a trend of decreasing BMI with 
increased PA. Participants reporting a “very low” activity level had an average BMI of 25.4, 
whereas participants reporting a “very high” activity level had an average BMI of 22.7. Response 
rates for BMI were 86.9%.  
 
Maximum length of education at enrolment was 40 years, minimum was 0. Mean years of 
education was 12.2 (sd 3.4). Education displayed a different distribution than BMI and age. 
While the difference between the groups was significant (p<0.001), these displayed a significant 
quadratic trend (p< 0.001) across PA levels, as shown in figure 5.4. Post Hoc tests reveal groups 
1 and 5 (“very low” and “very high”) to be quite similar (not significantly different, p=0.74). 
Furthermore, groups 2 and 3 (“low” and “moderate”) were significantly different from groups 1, 
4 and 5, but quite similar to one another (p=1.000). Of these, the “moderate” group had the 
smallest standard deviation (3.5 vs 3.3). In all groups, “high” was the only one significantly 
different from all the others (greatest p=0.012). The total response rate for length of education 





Figure 5.4 Mean education length within physical activity (PA) groups. 
 
Maximum alcohol consumption at enrolment was 203.8 grams per day, minimum was 0. Median 
alcohol consumption was 1.6 grams per day (90 percentile = 8.3). Because alcohol consumption 
was not normally distributed and had a few extreme values, median and percentiles was chosen 
as the measure of dispersion. When comparing groups, alcohol consumption means were 
significantly different between groups of PA (p<0.001). Post Hoc tests gave significant 
differences between groups “very low” and “very high”; “Low” to “moderate” and “very high”; 
“moderate”, in addition to “low”, also to “very high”; “high” to “very high”; and “very high” to 
all other categories, setting it apart as seen in figure 5.5. Test for linear trend remained significant 
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Figure 5.5 Level of alcohol consumption within physical activity (PA) groups. 
 
Smoking as reported at baseline differed significantly between groups “never”, “former” and 
“current” on PA groups (p<0.001). Figure 5.6 displays the variation in proportion of the three 
categories between the five groups. The Kruskal-Wallis non-parametric test indicated a falling 
mean rank from PA group 1-4, before an increase appeared between group 4 and group 5. This 
indicated that there were progressively fewer 1’s and 2’s (former, current) from group 1-4, before 
the number again increased to group 5. This could be explained by the increasing proportion 
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Figure 5.6 Proportion of never, former, and current smokers within physical activity (PA) groups. 
 
Diabetes at baseline was reported as not present or present. There was a mildly sloping trend 
towards smaller prevalence in higher PA groups. The Kruskal-Wallis test was significant with 
p<0.001. All mean ranks in the test decreased progressively with higher PA group. Total 
response rates for diabetes were 99.3%.  
 
Cancer was reported as any form of cancer present at enrolment. There was a decreasing trend in 
prevalence with higher PA group association. The Kruskal-Wallis test was significant with 
p<0.001. All mean ranks in the test decreased progressively with higher PA group. Total 
response rates for cancer were 100%. 
 
IHD was reported as any present condition of ischemic heart disease at enrolment. This included 
































in that mean rank dropped from PA group 1-4, before increasing and becoming larger than group 
3 in group 5. The Kruskal-Wallis test was significant at p< 0.001. Total response rates for IHD 
was 98.8%. As this was an ordinal variable and had to be compared using non-parametric tests, it 
was not possible to ascertain the individual difference between groups.  
 
Table 5.3 Distribution of covariates according to physical activity (PA) groups
1 
(reported as means and sd, or 
proportion and total group numbers. Total n respondents and proportion of total study population is reported for each 
variable): 































































































































































Tot. pop.:       76367 
        
1
 PA grouped “very low” – “very high”. 
2
 Alcohol consumption as measured in grams per day. 
3
 Smoking status at enrolment, reported as proportion “current” smoker.  
4
 Proportion diabetes at enrolment, “yes”.  
5
 Proportion any cancer at enrolment, “yes”. 
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5.2 Logistic regression analysis 
Results for age-adjusted and multivariable adjusted analysis are presented in table 5.4. Moderate 
level of PA was used as reference group to which all other PA groups were compared. Hosmer-
Lemeshow test results are reported in table 5.4. These indicate adequate goodness-of-fit for all 
four models. 
 
5.2.1 Main findings Chronic fatigue syndrome  
When adjusted for age, significant ORs were 1.90 (CI 1.65 – 2.19) for PA level very low, 1.34 
(CI 1.22 – 1.47) for PA level low, and 1.16 (CI 1.01 – 1.35) for PA level very high. Significance 
for PA trend was < 0.001 in age adjusted model. When adjusted for multivariate model, 
remaining significant ORs were 1.61 (CI 1.38 – 1.88) for PA level very low, 1.31 (CI 1.19 – 
1.44) for PA level low, and 1.18 (CI 1.01 – 1.38) for PA level very high. P for trend in 
multivariate model remained significant at < 0.001. The OR indicated a protective association 
between increasing levels of PA and CFS at 0.899. 
 
5.2.2 Main findings Back pain 
When adjusted for age, significant ORs were 1.20 (CI 1.08 – 1.34) for PA level very low, 1.08 
(CI 1.02 – 1.15) for PA level low, and 0.90 for PA level high (CI 0.85 – 0.96). Significance for 
PA trend was significant at < 0.001 in age adjusted model. When adjusted for multivariate model, 
only the OR of PA level very low remained significant at 1.17 (CI 1.04 – 1.31). P for trend in 




5.2.3 Main findings Fibromyalgia 
When adjusted for age, only PA level very low was significant with an OR of 1.49 (CI 1.24 – 
1.78). Significance for PA trend was < 0.001 in age adjusted model. When adjusted for 
multivariate model, this changed to OR 1.30 (CI 1.07 – 1.58). P for trend in multivariate model 
was significant 0.008. The OR indicated a protective association between increasing levels of PA 
and myalgia at 0.936.  
 
5.2.4 Main findings myalgia 
When adjusted for age, only PA level very low was significant with an OR of 1.20 (CI 1.08 – 
1.33). Significance for PA trend was < 0.001 in age adjusted model. The results were not 
significant adjusting for multivariate model, but remained close at OR 1.11 (CI 0.99 – 1.25). 
Other CIs lay generally close to the boarder of significance in myalgia, as seen in table 5.4. P for 





Table 5.4 Odds ratios (OR) and confidence intervals (CI) in age-adjusted and multivariate adjusted models for 
physical activity (PA) on chronic fatigue syndrome (CFS), back pain (BP), fibromyalgia (FM) and myalgia: 
 Age-adjusted:  Multivariable adjusted1:   
 OR (CI) P for trend2 OR (CI) P for trend2  Goodness-
of-fit3 
CFS     0.097 
PA  < 0.001   < 0.001  
Very low 1.90 (1.65 – 2.19)  1.61 (1.38 – 1.88)   
Low 1.34 (1.22 – 1.47)  1.31 (1.19 – 1.44)   
Moderate 1.00 (ref.)  1.00 (ref.)   
High 0.95 (0.86 – 1.04)  1.00 (0.90 – 1.11)   
Very High 1.16 (1.01 – 1.35)  1.18 (1.01 – 1.38)   
BP     0.919 
PA  < 0.001   < 0.001  
Very low 1.20 (1.08 – 1.34)  1.17 (1.04 – 1.31)   
Low 1.08 (1.02 – 1.15)  1.07 (0.99 – 1.14)   
Moderate 1.00 (ref.)  1.00 (ref.)   
High 0.90 (0.85 – 0.96)  0.95 (0.89 – 1.01)   
Very High 0.95 (0.86 - 1.05)  0.93 (0.84 – 1.04)   
FM     0.775 
PA  < 0.001   0.008   
Very low 1.49 (1.24 – 1.78)  1.30 (1.07 – 1.58)   
Low 1.12 (1.00 – 1.25)  1.09 (0.96 – 1.23)   
Moderate 1.00 (ref.)  1.00 (ref.)   
High 0.91 (0.82 – 1.02)  0.96 (0.85 – 1.08)   
Very High 1.05 (0.88 – 1.25)  0.99 (0.81 – 1.19)   
Myalgia     0.229 
PA  < 0.001   0.230   
Very low 1.20 (1.08 – 1.33)  1.11 (0.99 – 1.25)   
Low 1.06 (1.00 – 1.13)  1.03 (0.97 – 1.10)   
Moderate 1.00 (ref.)  1.00 (ref.)   
High 0.95 (0.90 – 1.00)  0.99 (0.93 – 1.05)   
Very High 1.01 (0.92 – 1.11)  1.05 (0.95 – 1.16)   
1
 Covariates in multivariate model: age, BMI, education, alcohol consumption, smoking. 
2
 Linear test for trend.  
3
 Goodness-of-fit as assessed with Hosmer-Lemeshow test. A non-significant result at the 5% level indicates model 











Our study set out to explore whether there was an association between self-reported PA and 
incidence of CFS, BP, FM, and myalgia among Norwegian women. The following discussion 
interprets the results from statistical description and analysis of data, with suggested explanations 
of results. Identified strengths and limitations in the present study were also assessed, as well as 
some implications for further research.  
 
6.1 Main findings 
Our study found that increasing levels of PA were significantly associated with a lowered risk of 
CFS, BP, and FM when assessed for trend. When comparing lower and higher PA levels to PA 
level moderate, we found that the lowest level of PA was associated with an increased risk of 
CFS, BP, and FM. For CFS, three out of four PA groups were significantly associated with 
increased risk of CFS, namely PA levels “very low”, “low” and “very high”. For myalgia, no PA 
levels were associated with an increased risk of the outcomes compared to moderate.  
 
6.1.1 Descriptive statistics 
Distribution of PA levels at enrolment was seemingly normally distributed. The largest group 
was those reporting to be moderately active, and there were more women in the two highest PA 
level groups than there were in the two lowest ones. According to Statistics Norway we would 
have expected at least approximately 6% of women to report “very low” levels of PA, given that 
this could be described as being physically inactive (26). Surprisingly, 5.1% reported being 
inactive, which marks this sample, consisting of women reporting baseline information from 
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1991 to 2003, as more active than the national average in 2012. In 1998, 39% of Norwegian 
women aged 25-66 reported exercising less than once a week (111), therefore we would have 
expected the normal distribution to be skewered more towards inactivity in our selection, but 
surprisingly found higher levels of PA to be more common among these women. The largest 
reported change in PA level in Norway the last two decades was from 2002 – 2005 when the 
proportion inactive women aged 45 – 66 fell from approximately 33% to around 24% (111). This 
implied no large changes in PA levels among women up until 2002. 
 
There was a significant difference in age between groups of PA, with a trend of decreasing age 
with increasing activity. Participants reporting “very low” PA were on average 1.5 years older 
than participants reporting “very high” PA. It follows that total PA levels often decrease when 
age increases because older people statistically move less (25).  
 
There was a similar pattern for the distribution of BMI in the selection, with “very low” PA 
having a BMI on average 2.7 greater than those women reporting very high PA. This put group 
“very low” at an average BMI of 25.4, which was above the WHO threshold for defining 
overweight (108). Decreasing PA during daily living increases the risk of gaining weight in an 
ever more sedentary society (76), and according to Shiri et al. a higher BMI will in turn decrease 
leisure time spent on PA (10), and thus further increase the health risks for this group.  
 
Alcohol consumption followed a diminishing linear trend, with consumption decreasing with 
higher levels of PA. Women reporting very high PA levels consumed the least alcohol and were 
consistently different from all other groups. Alcohol consumption dropped with increased PA, 
indicating a possibly healthier lifestyle with those that were the most active. This would be in line 
68 
 
with Kaczynski et al. when they suggested that level of PA could be a measure to identify the 
health profiles of different people (31). 
 
We would have expected trends similar to these covariates on PA for the other covariates 
included in the statistical model: education, smoking, and comorbidity. If PA levels indicate 
health profiles as suggested, then they could also be a measure of socioeconomic status (32). In 
that case, education, smoking, and comorbidity, which are also socioeconomically distributed, 
should follow the same patterns as BMI and alcohol in our study. Unexpectedly, they did not.  
 
Mean education level increased from PA group “very low” to group “high”, but then dropped to a 
level below that of “moderate” for PA group “very high”. Granted, the difference was only 0.8 
years between the two, but the deviation from the linear trend was quite noticeable as well as 
statistically significant. 
 
Proportion of current smokers decreased significantly with increasing PA levels except for the 
highest one where it increased to a level similar to those with the lowest PA levels. At the same 
time, proportion of never smokers followed a completely reverse trend, where those reporting 
very high PA levels once more came out similar to those with low PA levels. Since smoking has 
also been reported to be associated with lower socioeconomic status (31), this finding further 
indicated that PA in our study was not a linear proxy for socioeconomic status among 
participants. Regarding the nature of our exposure variable, being composed of several kinds of 
physical activity, we would not necessarily have expected PA alone to function as such a proxy.  
 
In addition to some lifestyle factors, health and disease also follow a social gradient to a certain 
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extent (112), especially IHD and diabetes (90). In our results, comorbidities did not contribute to 
any great extent in identifying what type of people PA group very high consisted of. 
Interestingly, incidence of all four outcomes followed a similar pattern to that of smoking. They 
decreased according to PA levels before consistently rising again from women reporting high 
levels of PA to those reporting very high levels, placing the incidence in group “high” 
somewhere between the levels of “very low” and “low”, or “low” and “moderate”.  
 
Of all PA groups, it was clear that the women who report “very low” PA appeared to be the ones 
with the most risk factors associated to them, as they scored consistently worse for important 
predictors of mortality and morbidity, such as BMI, education, smoking, and alcohol 
consumption. They also reported the highest levels of all comorbidities as well as outcomes. All 
these factors combined to suggest that this PA group was composed of those who most often are 
defined as belonging to lower socioeconomic strata, and have health profiles that reflect this. This 
suggested that PA corresponds to socioeconomic status and therefore to health profiles in the 
lower groups of PA levels.  
 
In thread with possibly not being a linear proxy, higher PA seemingly stopped denoting higher 
levels of socioeconomic status in PA group “very high”. As mentioned, women in PA group 
“very high” had an excess of smoking, less education, and more morbidity. It was interesting that 
PA did not continue to follow the simple, linear trend for covariates that are socioeconomically 
distributed. As mentioned previously, part of the explanation for this might be found in the 
measure of PA levels itself. Participants in the NOWAC study were asked to report their total 
amount of PA in daily living, which was specified to include PA when working at home or in an 
occupational setting, as well as exercise, and other forms of PA that could include activity when 
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commuting or during leisure time. As explored in the theory surrounding PA levels, Beenackers 
et al. found that those who spent the most time doing leisure time PA had the highest 
socioeconomic status (32). The findings of Bauman further indicated that those in high income 
countries which did not have physically intensive manual labor spent more time on leisure PA 
than those who did (27). Beenackers et al. further reported those with the lowest levels of 
education and socioeconomic status to also be those who were prone to having the most 
physically intensive work in the occupational setting. It has also been suggested that being 
physically active throughout the work-day might increase the desire to relax and be physically 
inactive during leisure time (79). Furthermore, those that have a physically intensive occupation 
would have to report that they are physically active throughout the work-day for several hours 
each day, most days of the week. From this it is possible to hypothesize that women who had a 
physically intensive occupation could be prone to categorize themselves as very physically 
active. It is possible that women reporting very high PA levels would be classified in a lower 
group if we had only been looking at leisure time PA, and by proxy, socioeconomic status.  
 
Studies have demonstrated that self-reported PA might be an acceptable way to rate PA level in a 
female population. Borch et al. reported a correlation between self-reported PA and objectively 
measured PA (113). This could indicate that the women reporting very high levels of PA actually 
did have this activity level. Subsequently, this might enhance their physical fitness, thus allowing 
them to reap the health benefits associated with such PA derived fitness. A possibly high level of 
physical fitness even among individuals with characteristics of lower socioeconomic strata, such 
as our “very high” group, could be explained by the increased popularity of leisure time PA in 
Norway. Levels of leisure time PA have increased in Norway during the last decade (26), and it 
has been demonstrated that high-income countries have a higher degree of total leisure time PA 
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(5). On the other hand, we have demonstrated participants in the present study who reported the 
very highest levels of PA to also display some lifestyle habits and incidences of morbidity that 
marked them as persons with health profiles possibly belonging to lower socioeconomic strata, 
suggesting they would not necessarily enjoy a protective effect of their PA level. Given their 
distribution of covariates and morbidities, we hypothesized that the sub-group type of PA they 
performed had a higher degree of influence over their health status than their total amount of PA 
did. This theory was supported by the systematic review of Beenackers et al. (32). 
 
6.1.2 Outcomes 
According to the cross tabulation of outcomes, the two outcomes CFS and FM appeared more 
often in combination with one or more other outcomes than by themselves. BP and myalgia 
appeared most often by themselves, but also frequently in combination with the other two. CFS 
and FM are the two outcomes that more closely resemble ‘syndromes', and which are similar to 
one another. The ‘symptomatic’ conditions, BP and myalgia, appeared by far most frequently, 
which should be no surprise considering their nature as pain symptoms. CFS and FM rarely 
figured on their own: approximately1/4
th
 of CFS cases appeared without any of the other three, 
while approximately 1/5
th
 of FM cases did. They also rarely appeared solely together: 0.1% of the 
study sample reported having both FM and CFS without having any of the two symptoms. 1.8% 
of the study sample reported having both FM and CFS in combination with one or both of the 
other two outcomes. This amounted to 1437 total cases of double-diagnosis of CFS in 
combination with FM, and was unexpected given the rather clearly defined diagnostic criteria 




The fact that most cases of CFS and FM appeared in combination with one or both of the pain-
symptoms could be explained by the fact that they could be symptoms of CFS and FM. 
Participants with CFS or FM could in the preliminary stages of these conditions experience cases 
of BP and/or myalgia as symptoms of these syndromes, but not identify them as such due to not 
having received a diagnosis of CFS or FM at that time. Both myalgia and BP lack the structured 
diagnostic criteria that CFS and FM have, and are diagnoses of exclusion. CFS and FM are 
diagnoses one receives from a physician, while BP and myalgia are common ailments that most 
people experience one or more times throughout their lifetime, and for which it is not required to 
get a doctors affirmation that one is experiencing.  
 
Theory on CFS and FM stated that they are two separate conditions and two discrete categories. 
However, theory has also demonstrated that they are similar with regards to symptoms and 
criteria, and that many patients who qualify for one also qualify for the other. It was unexpected 
that out of some 9000 total cases of CFS and FM, almost 1500 of these appeared at the same time 
with one another. We would have thought physicians to be more restrictive in the diagnostic 
process when one of these two conditions is already present. However, for a portion of cases – 
the prevalent ones - we did not know at what time conditions appeared in our sample; if they 
were diagnosed simultaneously or with a long interval. It should also be commented that we 
assume most of CFS and FM cases to have been diagnosed by a physician. Any reported case of 
these conditions that was not, we would not consider being a reliable incident case. However, we 
have no information whether participants had actually been diagnosed by a physician. An 
interesting subject for future research would be to assess diagnostic practices in the health care 
services today regarding double-diagnosis of CFS and FM, given that the overlap of these two in 
the current sample was representative for the general population.   
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The age standardized prevalence rates appeared to be quite similar overall to the prevalence rates 
of the selection in our study. The prevalence rates of 2.58% for CFS, 13.65% for BP, 5.02% for 
FM, and 17.87% for myalgia are comparable to the age standardized rates of 2.62%, 14.22%, 
5.03% and 18.09% respectively. This implies that the age groups of our study are representative 
of the mother population, Norwegian women. 
 
6.1.2.1 Chronic fatigue syndrome 
Incidence rate and prevalence rate for CFS were in our study calculated to be 411 per 100 000 
person years and 2.58%. Due to the gender differences in incidence and prevalence for this 
condition (16), numbers would most likely be lower for the Norwegian population as a whole. 
Incidence rates for both genders combined have been suggested to lie between 180-370 per 
100 000 person-years in other international settings (35). Other studies have reported female 
prevalence rates of CFS in two American settings to lie between 0.37% - 0.52% (33, 34). These 
studies performed telephone surveys of large local cohorts and performed clinical examinations 
of smaller subgroups of fatigued individuals to confirm or rule out a diagnosis of CFS. One 
review suggested world-wide prevalence rates at 0.4-1.0% for both genders combined (16) – this 
would be higher if for women only. The nationally representative prevalence rate of 2.58% found 
in our study was substantially higher than that of previously mentioned international studies. 
When interpreting this prevalence rate it is important to keep in mind that it was an aggregate of 
reported prevalence from several different time periods from both the 1990’s and the 2000’s. If 
the understanding and diagnostics of CFS differed to a significant degree across these time 
periods, that might have affected our calculated prevalence rate. However, as seen in the 
theoretical basis of CFS, this was unlikely to have had any large effect on our figures. Keeping 
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aware of the possible limitations of these numbers, they are nevertheless potentially some of the 
first indications of the level of CFS prevalence in Norwegian women. Norwegian health 
authorities have assumed national prevalence to follow international levels (36), while our 
numbers demonstrated national levels to be higher than those of other settings. 
 
As expected, multivariate p for trend displayed a significantly lowered risk of experiencing the 
outcome when increasing level of PA, starting from very low levels. When adjusted for in the 
multivariate logistic regression model, PA groups “very low”, “low”, and “very high” were 
significant predictors of CFS when compared to group “moderate”. Despite changes in ORs, no 
changes in statistical significance occurred when compared to the age-adjusted model. As 
expected, “very low” and “low” displayed an adverse effect on the risk of getting CFS when 
compared to “moderate”, with ORs 1.61 and 1.31 respectively. Unexpectedly, “very high” also 
displayed this kind of adverse effect, with an OR of 1.18. It is also interesting to note that being 
in PA group “high” made no significant difference from being in PA group “moderate”.  
 
Previous knowledge was lacking with regards to the association of levels of PA on the risk of 
developing CFS – a best estimate of what relationship PA might have was that moderate levels of 
PA could be hypothesized to have a protective association when compared to lower levels. Nijs et 
al. suggested that continued activity despite an increasing sense of sickness and loss of well-being 
might increase the likelihood of developing the condition (42). Therefore, we might also expect 
that those at risk of developing the disease would be more likely to do so the higher their activity 
level is. At a certain point, more activity might cause certain people to become sicker, faster. 
Therefore, the presence of a threshold level in PA’s protective effect might be plausible given the 
relatively limited knowledge available.  
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Based on theory of PA in general, and hypothesis on PA’s association with CFS in specific, the 
results of the present study seemed to fit the pattern. Lower levels of PA progressively increased 
the risk of developing the condition, with sedentary levels giving the highest risk. PA levels 
higher than moderate seemed to have a diminishing protective association, with the uppermost 
levels of PA exacerbating the risk of developing CFS. This indicated that the theorized threshold 
level might exist, and be located somewhere between PA levels “high” and “very high” in our 
selection. While the women reporting high levels of PA did not have a risk that was significantly 
different from that of “moderate”, “very high” did. This also indicated that comparing groups of 
PA and their association to the risk of developing CFS was more accurate than looking at p for 
trend of PA. 
 
However, it is by no means certain that this increased risk was attributable to a possible threshold 
level in PA alone. PA group “very high” had some other characteristics that have been previously 
theorized to make this group have a generally higher risk of contracting disease. As 
demonstrated, PA group “very high” had a distribution of covariate factors that in some cases 
made this group’s characteristics more similar to the lowest PA groups than to PA group “high”. 
For women reporting very high PA levels that had a distribution of confounders placing them in 
higher socioeconomic strata, theory has indicated that most PA time is spent on leisure time 
activity (32). As they reported the very highest level of PA, their threshold for refraining from 
activity could be thought to be quite high as well – making them more likely to insist on 
maintaining a high level of activity despite a sense of sickness and loss of well-being. This might 
have explained their increased risk of developing CFS, given that they have one. On the other 
hand, descriptive statistics displayed how many in the PA group “very high” possibly fit into 
lower socioeconomic strata, with all the added hardships this entails. Physically intensive 
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occupations often have a negative impact upon health (30), and stress and dramatic life changes 
have been shown to result in an increased risk of developing CFS (35).  
 
Based on our results, we suggest the hypothesis that lower levels of PA as compared to moderate 
levels are a risk factor for developing CFS as for many other diseases and disorders. We also 
suggest the presence of a possible threshold level in the extreme high PA levels, where PA stops 
being a protective factor and assumes the role of a risk factor for developing CFS. It is unclear 
whether this threshold level was attributable to amount of PA in itself, or the type of PA that 
different socioeconomic groups most frequently performed. This last suggestion is based on 
limited available knowledge and the findings of our study, and would be suitable for further 
exploration by other studies.  
 
6.1.2.2 Back pain 
Previously discussed theory indicated that incidence and prevalence of BP would be higher in 
women than men (53). Incidence rate and prevalence rate for BP in our study were found to be 
1268 per 100 000 person-years and 13.65%, respectively. Our incidence rate was low compared 
to incidence rates of other studies. Being a conservative estimate, this prevalence was still within 
the previously reported lifetime prevalence rates 11-84% (1, 3) reported in a systematic review of 
population prevalence of LBP. One reason why a lower prevalence was reported here than in 
some other studies, might be the fact that some of the highest age groups were not included. 
Prevalence of BP has been demonstrated to remain constant across all age groups (53). Most 
likely, our low numbers were attributable to the fact that mean age of participants reporting BP 
prevalence in our study was 48.3 (± 8.6) years, and included age groups were 34-70. This means 
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that those who reported prevalent BP had on average only lived slightly more than half of their 
expected lifetime in which to experience BP. If the reported constancy of prevalence across age 
groups is correct, this means that some of our participants were yet to experience BP at a later 
point in life. Our prevalence might be lower than some other reported prevalence rates due to our 
study looking solely at BP of unknown origin. In addition, it is possible that the women of our 
study had a high threshold for reporting an experience as BP due to the non-explanative phrasing 
of the BP item in the questionnaire. Senie however reported that women in general reported 
higher consequences of BP (53), which might indicate that they were more liable to report cases 
of BP. Overall, we might still have expected a higher reported prevalence of BP than what was 
the case. 
 
Results from multivariate logistic regression analysis showed a significant P for trend, indicating 
a lower risk of experiencing BP with increased PA level. Categorical comparison displayed a 
significantly increased risk of BP for PA groups “very low” and “low”, as well as a reduced risk 
for PA group “high”, when adjusting for age. When including additional confounders however, 
only PA group “very low” remained significant for increased risk of BP. This result seemed to be 
mostly in concordance with what theory suggested, that moderate levels of PA could be 
protective against BP when compared to lower levels (50). A ceiling effect to this protective 
effect has been suggested, so that higher levels of PA do not necessarily lower the risk of BP any 
further (50, 55). This theory predicted that we might have expected low PA levels also to be a 
risk factor of BP when compared to moderate, but this was not found in our study. Thiese et al. 
also reported very high levels of PA to be a risk factor for developing BP of equal importance to 
very low levels (50). The fact that PA group “very high” was not a statistically significant risk 
factor in our study, and that its OR and CI were quite different from those of “very low”, was 
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unexpected. This is especially true when considering how similar group “very low” and “very 
high” were with regards to the descriptive characteristics of these two groups. With so many 
similar risk factors, we would have expected results for these two PA groups from the present 
analysis to resemble one another more closely. Yet it remained that the only mentionable factor 
separating these two groups was their level of PA. Thus, theory outlined two levels of risk; that of 
low levels of PA and that of moderate levels, and suggested the risk of very high levels of PA to 
resemble that of low. Yet in our study we found that very high level of PA did not have 
significantly different risk of BP than that of moderate. This might be a topic of interest for future 
studies. Additionally, the difference between our study and previously discussed theory might 
serve to point out the difference between total levels of PA and PA as leisure time 
activity/exercise. 
 
The fact that very low level of PA was a risk factor for experiencing BP could be explained by 
the adverse effect that inactivity has on the musculoskeletal system. Lee et al. reported on the 
correlation between PA and cardiorespiratory and muscular fitness, as well as a positive effect on 
the composition of body tissues (7). Sedentary individuals have been shown to have an 
unhealthier body mass and composition (7), and Shiri et al. documented the association between 
obesity and increased risk of BP, an association increasingly present in women (10). As well as 
being significantly associated with an increased risk of BP, the women in our study reporting 
very low levels of PA also had the highest mean BMI in the selection. Their stated activity level 
indicated that their heightened BMI was not attributable to excessive muscle tissue, but probably 
to that of unhealthy body composition. These women also had the shortest length of education, 
indicating that among them would be found a higher number of individuals working in more 
physically intensive occupational settings. This form of PA might adversely affect health and 
79 
 
well-being (30, 32). Further explanation for the effect of inactivity on risk of BP could be found 
in the biopsychosocial understanding of this condition. As discussed in relation to CFS, those 
who reported a very low level of PA had certain characteristics identifying them as belonging to 
certain socioeconomic strata, to which is connected some social determinants of health in form of 
habit, culture and economy (112, 114). These social determinants can be understood as causes of 
lowered PA. For instance, those who reported PA levels “very low” were also those who smoked 
the most  (31), which was not surprising given their low levels of education; a relationship that 
has previously been well demonstrated (115, 116). Smoking is a risk factor for developing BP by 
itself (15, 84), adding to the burden of disease in this group. But more than being only a 
determinant of BP in itself, smoking is also associated with lowered levels of PA (31, 88), given 
the effect of smoking on the cardiorespiratory system which is crucial for the ability to perform 
physically intensive activity. As confounders have been controlled for in the statistical modeling, 
it might appear as if the association between PA and risk of BP remained important, but that the 
level of PA itself could be a result of underlying causes. 
 
There were some unexpected results with regards to the association of very high PA levels to the 
risk of BP. These results should be interpreted with the understanding that what was meant by BP 
in the NOWAC questionnaire, and subsequently understood by the participating women to be so, 
did not necessarily reflect what is meant by such terms in other studies. As previously discussed, 
the NOWAC study does not contain any explicit definition of what is meant with BP beyond 
being of unknown origin. Therefore it is possible that prevalence and incidence were not 
ascertained in an optimal manner. BP of unknown origin remains a subjective experience and a 
condition defined by exclusion of other, known causes of BP. What the women of our study 
chose to define and report as BP would be subject to individual interpretation. We suggest that 
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further population based work should take care to standardize a definition of ‘back pain of 
unknown origin’.  
 
6.1.2.3 Fibromyalgia 
Incidence rate and total prevalence were also calculated for FM. We calculated them to be 287 
per 100 000 person-years and 5.02%, respectively. As before, numbers were based on women 
only, and will therefore be higher than those of the Norwegian population as a whole due to the 
previously discussed higher risk for FM in women. These rates remain conservative estimates. Of 
the international studies reporting FM prevalence, many reported that of the US national setting. 
Several of these reported identical rates (57, 59, 117), and they all referred to the same original 
source; that of Wolfe et al. from 1995. They conducted an interview of 3006 subjects in Wichita, 
Kansas. 391 of these underwent physical examination in order to diagnose FM on basis of ACR 
criteria (64). This was the study reporting a prevalence rate of 3.4% in women and 0.5% in men. 
Our prevalence rate of 5.02% for women is representative of the Norwegian female population. 
There are few present comparative epidemiologic numbers of female rates for FM in the 
Norwegian population, but one source reported a female prevalence rate of 5% (2). Subjects with 
prevalent FM in our study had an average age of 49.1 (±7.9) years and were between 34-70 years 
of age. Our numbers add to the limited epidemiological knowledge of FM in Norway today, and 
imply that as with CFS, FM numbers may be higher in the population than what has previously 
been reported.   
 
Multivariate p for trend again displayed a significantly lowered risk of experiencing the outcome 
with increasing level of PA, starting from very low levels. As with CFS, the models for FM did 
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not differ in terms of significance of PA levels between age adjusted and multivariate adjusted 
models. When performing categorical comparison, the only statistically significant association 
between PA and FM was found for level “very low”, with an OR of 1.30. In both models, the CI 
for group “low” was close to being significant, and its overlap of 1 was skewered towards the 
right so that we would have expected “low” level of PA to also be a risk factor for developing 
FM. As for all other outcomes, moderate PA levels were the reference levels, indicating that 
being less than moderately active was a risk factor associated with developing FM. Higher levels 
of PA did not display statistically significant associations with FM. However, while the CI of 
“high” was somewhat skewered towards the left, indicating a potentially protective association, 
that of “very high” was more ambiguous. The fact that neither “very high” nor “low” displayed 
statistical significance was surprising, given the close relationship between FM and CFS 
regarding the nature of the conditions and the people who develop them (19, 61). With a 
suggested overlap of up to 80% of patients who fit the diagnostic criteria of both FM and CFS 
(59), and given the previously discussed characteristics of PA group “very high”, we would have 
expected the association between PA and these two outcomes to closely resemble one another.  
 
Among other theories, the review by Mease from 2005 suggested precipitating causes of FM to 
be stress, medical illness, and pain conditions (59). We know that PA by itself alleviates and 
could prevent such processes in the body when composed of the protective kind of activity. At 
the same time, inactivity is associated with a higher prevalence of depression, anxiety, MSDs, 
and other painful conditions (7, 118-120). It is possible to theorize that this pathophysiological 
sum of inactivity could be a predictor for developing FM based on the scarce evidence base for 




In addition to these possible physiological and psychological causes, Lærum et al. have suggested 
that the development of FM must be interpreted in a biopsychosocial model with a combination 
of physiological, psychological, and cultural aspects of daily living as possible explanations (2). 
As we have reported above, inactive respondents in our study have characteristics corresponding 
to that of low socioeconomic status and are through this at higher risk of multiple causes of 
morbidity and mortality.  
 
We did not expect to see non-significant findings for PA groups “low” and “very high”. For the 
socioeconomic argument to be strengthened, based on what we have previously discussed on PA 
group “very high”, this group should have displayed a risk similar to that of the risk of CFS for 
this group. Possibly, CFS and FM differ with respect to the protective effect of PA. Adding to 
this is the fact that the central aspect of CFS is fatigue, which is the theoretical explanation of 
why very high activity level might increase the risk of developing CFS (42). In FM, widespread 
pain is more central than fatigue, which might not be as easily exacerbated by more activity as is 
fatigue. Similarity of risk factors for these two conditions would be an interesting topic for 
further research. These results suggested that maintaining CFS and FM as two separate 
conditions might be appropriate. 
 
For both “low” and “very high”, we must also keep in mind that “moderate” PA was the group to 
which they were compared. Thus, our results showed that there was little difference in associated 
risk of developing FM between being in PA group “low”, “moderate”, “high”, and “very high”. 
This could imply a possible threshold level for FM indicating that any higher activity level is 
better than very low activity when it comes to reducing the risk of developing FM. However, this 
is not a phenomenon that has been previously suggested by theory behind FM - despite being 
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suggested in general theory about the effect of PA. Thus, caution should be used when inferring 
to the clinical importance of levels of PA for risk of developing FM.  
 
6.1.2.4 Myalgia 
Our study calculated an incidence rate and prevalence rate of 1509 per 100 000 person-years and 
17.87%, respectively. Muscle pain/myalgia is another condition that could occur several times in 
the same individual during life. In the NOWAC study, it was not possible for one individual to 
report any outcome more than once. Therefore, incidence rate would most likely have been 
higher had the NOWAC study allowed for multiple reporting of conditions which can be 
recurrent. Respondents reporting prevalent cases were between 34-70 years of age and had a 
mean age of 48.3 (± 8.3) years. Estimates remain conservative as discussed, and only apply to 
women. Myalgia was the phenomenon most frequently reported by the women in our study. Due 
to some methodological issues when describing muscle pain/myalgia as a reporting item, and 
standardizing this as a measurement, comparative numbers of incidence and prevalence are 
difficult to find. Participants in our study were asked to report whether they had experienced 
‘muscle pain (myalgia)’ at any point during a given time interval. How the respondent chose to 
interpret this question would determine what was reported as muscle pain/myalgia, rather than 
the clinical or theoretical understanding of what muscle pain/myalgia is. In fact, muscle pain 
differs from the other conditions relevant to our study in that it, to an even larger extent than BP, 
is a symptom and cannot be described as a syndrome or disease in itself. Theory states that causes 
of muscle pain/myalgia are many and diverse. In the cross-tabulation of outcomes, myalgia was 
constantly present in all the largest groups of combined outcomes, indicating that it might be 
frequently reported in people who have experienced other MSDs in which musculoskeletal pain 
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is a central symptom.  
 
For myalgia, multivariate analysis of PA levels displayed a protective but not statistically 
significant trend for increasing PA levels. Regarding PA groups, group “very low” was 
statistically significantly associated with an increased risk of reporting myalgia, when adjusted 
for age. This significance disappeared once the multivariable logistic regression model was 
included. Evaluating ORs, only PA group “high” had a protective association beyond that of 
comparator “moderate”, whilst all other levels indicated increased risk of experiencing the 
outcome. No groups reached statistical significance. We do not regard these results as 
unexpected, given the inherent ambiguity of the outcome item in question.  
 
Most people will experience what can be termed ‘muscle pain’ at one or several times during 
their lives (68). It was therefore unexpected that reported numbers of incidence and prevalence of 
muscle pain were not higher than what was reported in our study, although in the case of 
prevalence, there still remained time at risk for most respondents and so the rate might still have 
increased in time. Including both incident and prevalent cases, more than 20 000 women reported 
having experienced a phenomenon identifiable as muscle pain or myalgia. While this was 
unexpectedly few, it remained the largest reported outcome group, indicating that it was the most 
commonly occurring outcome. This was to be expected, given its position as a symptomatic 
condition. In our study, it was evident that level of PA was not strongly associated with risk of 
experiencing this outcome. All PA groups experience it to a similar degree. This could still mean 
that some types of muscle pains are more frequent in certain PA level groups than others, but the 
manner in which myalgia was defined leaves the item too broad and unspecific to differentiate 
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between types of muscle pain. The heterogeneity of what has been reported could be seen as too 
high to be compounded into one outcome measurement which could accurately measure one 
discrete phenomenon. Sources of muscle pain could include delayed onset muscle soreness after 
strenuous exercise, as a symptom of pathophysiological processes, as a result of injury, due to 
MSDs of unknown origin, and as early signs of the other three outcomes of our study. In the 
same way the term ‘muscle pain’ is too general, so also the term ‘myalgia’ could be too narrow. 
It is not certain that the lay-woman was capable of identifying what condition was meant by this 
term, and might therefore underreport cases of myalgia owing to the fact that she had never 
received such a diagnosis by a physician. The fact that incidence and prevalence rates were 
unexpectedly low might indicate that the presence of the term ‘myalgia’ in the questionnaire item 
was confusing for some respondents and deterred them from reporting this or identifying 
experienced conditions with this term. This is a hypothesis which could be explored in a 
validation-type study. 
 
Results regarding myalgia from our study need to be interpreted cautiously, as what was meant 
by respondents when reporting having experienced muscle pain/myalgia might be any number of 
pain conditions, resulting from an equal number of different causes. We can by these results 
register how large a proportion of the included women report experiencing a phenomenon they 
identify as muscle pain/myalgia. Future projects should strive to define and more clearly describe 
what condition is the desired object of questions regarding muscle pain, to ease respondents’ 
understanding and allow accurate reporting. This ambiguity regarding the term myalgia is 




6.2 Main strengths and limitations of our study 
There were a number of possible strengths and limitations associated with our study. These 
mainly related to the NOWAC study from which data material was gathered, and the type of 
methodology applied when analyzing this.  
 
The NOWAC study is based on self-reported data, which is time-efficient and incurs a lower cost 
than other forms of measurement (110). Because the results of our study depended on what 
information respondents chose to disclose, so too did the internal validity. External validity 
depended on whether the selection was representative for that of the source population, namely 
Norwegian middle-aged women. 
 
6.2.1. Strengths of our study 
One of the strengths of our study was that data from participants had been internally and 
externally validated. The sample was drawn randomly from the source population. Self-reported 
data involve an amount of uncertainty regarding the reliability of information given by 
respondents. This can be attributed to a self-selection bias that can occur in studies based on 
voluntary participation, giving the “healthy volunteer effect” (105). According to previously 
performed studies, the NOWAC study population did not differ significantly from the 
corresponding age groups of the source population from which it was drawn, except for a slightly 
higher level of mean education length (105). Due to the representative nature of the NOWAC 
study, results from our study will be possible to generalize to the female population of Norway in 
corresponding age groups, and can therefore be used as basis of future hypotheses and 
development of evidence bases. Epidemiologic data described in our study will be valid for the 
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main population, meaning that our study contributes important information on both prevalence 
and incidence rates in the Norwegian female population that have previously been scarce.  
 
Respondent rates for enrolment and follow-ups in the NOWAC study were about 55% and 80% 
respectively. There was a dropout between baseline measurements and first and second follow-up 
due to participants electing not to return a filled-in questionnaire. Examinations were done to test 
whether the differences in response rates affected the distribution of exposure variables in the 
samples. No statistically significant differences were found (105). This indicates that dropout 
rates should not be a problem due to the established validity of remaining participants. 
 
For inclusion into the present study, only participants reporting PA levels at baseline fit the 
inclusion criteria. 74.5% of the original cohort baseline participants met inclusion criteria for 
participation in our study. Of those returning a filled-in questionnaire during the first follow-up, 
54% were included in the second follow-up. Descriptive statistics of covariates were gathered 
from participants in the second follow-up and manually compared to those of the baseline 
participants. Statistical comparison was beyond the scope of our study, but manual inspection 
indicated marginal differences between baseline and second follow-up participants. Perhaps most 
importantly, participants in the second follow-up were slightly younger on average, causing such 
variables as BMI and morbidity to also be slightly differently distributed than in the baseline 
population. Second follow-up participants were never more than 4.6 years younger on average 
than baseline (in PA group “very low”), which was to be expected given that a mean follow up 
time of 13.1 years between baseline and second follow-up would most likely cause a proportion 
of the oldest participants at baseline enrolment to drop out by the time of the second follow-up, 
due to death or other reasons. However, Lund et al. reported older women in some settings to 
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have higher response rates (105). This might indicate a potential bias in the data, but we maintain 
that attrition rates are normal and expected for this type of studies, and that differences appeared 
to be small in our study.  
 
To ascertain the validity of the exposure variable used in our study, the correlation between self-
reported PA and objectively measured PA have previously been validated (113). They concluded 
that there were “modest correlations compared with criterion measures, making this self-report 
instrument suitable to differentiate general PA levels in an adult female population in Norway” 
(113). This indicated that the manner of measuring the exposure variable chosen for our study is a 
reliable method of measuring levels of PA in populations and therefore was suitable to rank the 
participants’ PA level.  The NOWAC study was not designed to look at PA as a primary 
exposure. Nevertheless, it has the advantage of asking for a summary measure of total PA based 
on the same kind of sub-categories of PA that have been suggested in theory (24, 28), yielding an 
exposure measurement that accounts for all these diverse forms of PA. Possibly, future studies 
can attempt to differentiate between the sub-categories of PA to explore the individual effect 
estimates of these with regards to risks. In particular, the difference between leisure versus 
occupational PA might be interesting to investigate, given their potentially inverse nature in 
relation to health as suggested by theory. 
 
Validation studies have been performed for many of the covariates of interest to our study (103): 
  
With self-reported BMI, one study found underestimation of weight and overestimation of height 
to occur in women (121). Younger women underestimated their weight the most. Those who 
were underweight more often reported a higher weight, and those who were obese more often 
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reported a lower weight. However, regarding the present study, work has been done to validate 
self-reported BMI as a measurement of women’s height and weight. Borch referred to personal 
communication with Dr. Eiliv Lund and Mrs. Nicolle Mode, University of Tromsø, Norway, 
regarding so far unpublished results (122). They suggested that BMI appears to be a valid 
measure in the NOWAC study when compared to height and weight measured by health 
professional staff. 
 
A study by Rylander et al. concluded self-reported diabetes in the NOWAC study to be a valid 
measurement of presence of diabetes. They also concluded that missing answers could be reliably 
interpreted as not having the disease (123).  
 
Through personal communication, Dr. Lund reported that among 50 self-reported MI, 35 (70%) 
were verified through medical case histories as definitely having had a MI. Possible MI was 
identified in 2 cases (4%), 3 (6%) were definite or possible MI cases (not specifiable) and 6 
(12%) were angina pectoris cases. Only 5 cases were identified as definitely not having had MI 
(10%) (Unpublished). Assuming that the participants were not systematically different from the 
non-participants, self-reported MI may overall be considered more or less valid among 
Norwegian women of the NOWAC study (Professor Eiliv Lund, ISM, UiT; personal 
communication). 
 
Social desirability bias has been suggested to cause underreporting of smoking in self-reports, 
thus creating a possible bias towards the null (124). Regardless, as smoking is not measured by 
amount, but rather by absolute status (never – former – current), underreporting of former/current 
was not likely to occur to any large extent. 
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Mean follow up time between baseline measurements and the two rounds of follow-up was 
sufficiently long to allow for the development of outcomes in participants and therefore for the 
detection of incident cases. The fact that exposure was measured at baseline also gave a certain 
temporal indication between exposure and outcomes, and could serve to form a causal hypothesis 
on the relationship between exposure and outcome variables.  
 
One of the strengths in our study was its large and representative number of participants. Robust 
numbers of respondents significantly lowered the chance of random errors affecting the effect 
estimates from analysis. This also implied that the epidemiologic data on incidence and 
prevalence discovered in our study were equally robust, and would resemble the corresponding 
distributions in the source population. Accounting for the different time periods when calculating 
incidence rate also allowed for a more precise calculation. The information gathered through the 
NOWAC study also had the benefit of allowing us to control for important lifestyle factors as 
possible confounders. Sensitivity analysis of comorbidity covariates allowed us to apply logistic 
regression for dichotomous outcomes with the smallest possible model, in accordance with the 
principle of parsimony (125). Use of exposure variable and confounders in our study was done in 
concordance with what previous studies on the same study population have demonstrated (122), 
and appeared to be appropriate for these types of variables as discussed in section 4. 
 
6.2.2 Limitations of our study 
We identified some possible limitations associated with our study.  
 
As discussed, there were missing data for some covariates included in our study. Several kinds of 
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bias may be associated with non-item response for lifestyle data. Missing cases in analysis are 
reported in table 4.1. No action was taken to impute for missing data in the covariates. The 
highest amount of proportion missing data was 22.6%. Descriptive statistics in our study 
identified alcohol to be the variable most prone to non-item response, causing these participants 
to be missing from analysis when alcohol was included in the logistic model. This was 
understandable given that some series of the NOWAC study did not include alcohol as a 
reporting item. There was a possibility that there were some systematic similarities between these 
missing participants that we were unaware of and which could have caused a bias in our results. 
These possibilities of bias when reporting lifestyle habits may have served to skewer the 
distribution of confounding factors and underestimate their effect on the association between PA 
and the outcomes of interest. Previously discussed validation studies indicate that much of the 
data material might be free of substantial amounts of bias.  
 
Studies have found that alcohol is often underreported in studies with self-administered 
responses. The “social desirability bias” has been shown to cause respondents to not reply 
accurately on items regarding alcohol consumption. Respondents tend to underreport and/or 
underestimate their own levels of consumption, frequency of drinking, and daily reported 
consumption, as well as the consequences of drinking (126). This means it should be expected 
that actual alcohol consumption is higher than what is apparent from self-reporting.  
 
One possible limitation of the exposure measurement was the wide time-span that the study 
gathered baseline information from. The first baseline was gathered in 1991, while the most 
recent one was done in 2003. Those of our selection that participated in baseline reporting at 
some point after the year 2000 could have had a rather different lifestyle with regards to PA and 
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leisure time PA, than those who did so in the early 90’s. A possible implication of this is that one 
should be cautious with assuming homogeneity in a baseline group spanning two decades with 
regards to the different sub-categories within PA. What became contained within the exposure 
measurement of total PA could be quite different depending on whether this was measured in the 
1990’s or 2000’s. Results from analysis will have to be interpreted with this in mind. Sub-group 
analysis on PA between the decades was beyond the scope of our study, but a study on PA and 
risk of postmenopausal breast cancer in the NOWAC study by Borch et al. found no large 
differences in distribution of covariates over PA level (122).  
 
Another possible limitation with regards to exposure and confounders was the fact that these 
were all gathered from baseline. Max follow-up time was 15 years, giving participants at most 
these many years to change their lifestyle habits and therefore confounding the association of PA 
to outcomes by an unknown magnitude due to having a true exposure that was of a different 
magnitude than what was reported at baseline.  
 
Theory suggests some difficulties with regards to the four different outcomes of interest. Firstly, 
the NOWAC study is not designed to measure these four conditions as outcomes, which was 
evident in the ambiguity regarding these reporting items as discussed above. Secondly, there was 
some development of diagnostic routines regarding both CFS and FM during the 1990s. This 
could imply that some unknown proportion of the reported incidence found in our study was 
actually attributable to recent diagnosis of pre-existing conditions being identified during the 
same period that the first baseline information was gathered for our study. This could 
underestimate prevalence and overestimate incidence of these conditions among Norwegian 
women. However, our study set out to investigate the association between self-reported PA and 
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self-reported MSDs. For future studies, it would be interesting to validate self-reported MSDs 
with general practitioners’ confirmations or patient journal information.  
 
We expect that there might be some residual confounding that has not been adjusted for in our 
analysis, possibly due to the distance in time between baseline and follow-ups, or due to other 
confounding variables having not been included in analysis.  
 
6.3 Implications for further research 
Our study implies that there are data available for calculating prevalence and incidence of 
common causes of disability and sick leave among Norwegian women. Future studies should 
attempt to verify prevalence and incidence rates of the outcomes of our study.  
 
PA appeared to be differently associated with each of the four outcomes of our study. Future 
studies should take this into consideration and keep them separate as outcome measures. 
Validation studies can attempt to establish the validity of self-reported outcomes by comparing 
self-reported information with patient journals or possibly by establishing the conditions through 
physical examination.  
 
It has been reported that “the contradictory inequalities for total PA may partially be explained by 
the contrasting socioeconomic patterns found for leisure time PA and occupational PA” (32). It 
would be interesting for future studies to investigate each of these two PA categories’ individual 




Finally, the NOWAC study by the nature of its design only examines health effects of exposures 
on outcomes for women. Regarding knowledge of the great disparities between genders for the 
outcomes investigated in our study, it will be interesting to compare Norwegian genders to each 
other.   
 
6.3 Conclusion 
In a nationally representative cohort of Norwegian women aged 34-70, incidence densities per 
100 000 person-years were calculated to be as follows: CFS 411, BP 1268, FM 287, and myalgia 
1509. Prevalence rates were found to be 2.58% for CFS, 13.65% for BP, 5.02% for FM, and 
17.87% for myalgia. These were comparable to age-standardized rates for the corresponding 
Norwegian female population. In logistic regression analysis, when compared to moderate PA 
levels, we found that very low PA levels were associated with an increased risk of CFS, BP, and 
FM. Low PA levels were associated with an increased risk of CFS. Very high PA levels were 
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